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 CCAAT/enhancer-binding protein (C/EBP) β and C/EBPδ are known to participate 
in the regulation of many genes associated with inflammation. However, little is known 
about the activation and function of C/EBPβ and -δ in inflammatory responses elicited by 
Fcγ receptor (FcγR) activation. Here I showed that C/EBPβ and -δ activation were induced 
in immunoglobulin G immune complex (IgG IC)-treated macrophages by using gel shift 
assays. The increased expression of C/EBPβ and -δ occurred at both mRNA and protein 
levels. Furthermore, induction of C/EBPβ and -δ was mediated, to a large extent, by 
activating FcγRs. Using small interfering RNA (siRNA)-mediated knockdown as well as 
macrophages deficient for C/EBPβ and/or -δ, I demonstrated that C/EBPβ and -δ played a 
critical role in the production of tumor necrosis factor-α (TNF-α), macrophage 
inflammatory protein-2 (MIP-2), and macrophage inflammatory protein- 1α (MIP-1α) in 
IgG IC-stimulated macrophages. Moreover, both extracellular signal-regulated kinase 1/2 
(ERK1/2) and p38 mitogen activated protein kinase (MAPK) were involved in C/EBP 
induction and TNF-α, MIP-2, and MIP-1α production induced by IgG IC. I provided the 
evidence that complement component 5a (C5a) regulated IgG immune complex-induced 
inflammatory responses in macrophages by enhancing ERK1/2 and p38 MAPK activities 
as well as C/EBPβ and -δ activities. To further explore the roles of C/EBPβ and C/EBPδ in 
FcγR-mediated inflammatory responses in vivo, I used IgG IC-induced acute lung injury 
model. I showed that both C/EBPβ and C/EBPδ activation were triggered in lungs
 xiii
challenged by IgG IC. I further demonstrated that C/EBPβ but not C/EBPδ deficient mice 
displayed significant attenuation of pulmonary vascular permeability and neutrophil 
accumulation when compared with wild type mice. Moreover, C/EBPβ deficient mice 
expressed considerable less inflammatory mediators compared with wild type littermates. 
Together, these data indicate that both C/EBPβ and C/EBPδ act as inflammatory 
stimulators in vitro during IgG IC-mediated inflammation. However, it is C/EBPβ but not 




IgG IC-induced Acute Pulmonary Inflammation 
Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are 
important problems in human beings, leading to 75,000 deaths each year in the United 
States (1). To dissect the molecular mechanisms of ALI and ARDS, a number of animal 
models have been developed. By using animal models to mimic pulmonary inflammation, 
we can explore possible signaling cascades involved in inflammation-related lung damages. 
Such experimental models do not necessarily reproduce what happened during human 
pulmonary inflammation, but they allow us to investigate the molecular mechanisms that 
result in damages of pulmonary endothelial barrier and alveolar epithelial barrier. In 
addition, information obtained from experimental lung inflammatory models is beneficial 
to understating of inflammation-mediated diseases in other organs. In my dissertation, IgG 
IC-induced ALI in rodents is used. The model is applied to determine the roles of cytokines, 
chemokines and the complement system in inflammation, although IgG IC-induced tissue 
injury in human beings is mainly observed during autoimmune diseases, such as immune 
thrombocytopenia, systemic lupus erythematosus, extrinsic allergic alveolitis, and 
rheumatoid arthritis (2-5). IgG IC-stimulated ALI is initiated by intratracheal injection of 
IgG antibodies against bovine serum albumin (BSA), followed by intravenous 
administration of BSA. After IgG IC formation in the lung, damages of interstitial
 2
capillary endothelial cells and alveolar epithelial cells are induced through a series of 
pathophysiological events. 
Effects of FcRs on IgG IC-mediated Immune Responses 
IgG IC-induced immune responses is achieved by binding of IgG IC to FcRs. 
FcγRs, which can specifically bind to the Fc region of IgG, are divided into four classes. 
Three classes of activating FcγRs are discovered: 1) FcγRⅠ with high affinity for Fc 
region of IgG; 2) FcγRⅣ with intermediate affinity; 3) FcγRⅢ with low affinity (6, 7). All 
these FcγRs share a common FcR γ-chain containing an immunoreceptor tyrosine-based 
activation motif (ITAM) in the cytoplasm, which is indispensible for cell activation (8). 
Association of IgG IC with FcγRⅠ/FcγRⅢ/FcγRⅣresults in signal transduction from 
cytoplasm to the nucleus, which is achieved by interaction between the  chain 
formed-homodimer and the receptor α chain (6, 9). IgG IC-induced clustering of FcγRⅠ
/FcγRⅢ /FcγRⅣ stimulates tyrosine phosphorylation within ITAM and subsequent 
activation of downstream signaling cascades involved in functional responses (6). Because 
FcγRⅡ, with low affinity for Fc region of IgG, has an immunoreceptor tyrosine-based 
inhibition motif (ITIM), which can abrogate activation signaling induced by ITAM, it 
functions as an inhibitory FcγR (3, 8). FcγRⅠis constitutively expressed by macrophages, 
monocytes and human airway smooth muscle cells while FcγRⅢ can be found on the 
surfaces of many types of cells, such as natural killer, eosinophils, macrophages, 
neutrophils, monocytes, human airway smooth muscle cells and platelets (10, 11). FcγRⅡ
is expressed by almost all hematopoietic cells and human airway smooth muscle cells (10, 
11). FcγRⅣ, a recently identified IgG IC receptor, is restricted to myeloid lineage cells (7).
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The mechanisms by which IgG IC induces inflammation remain largely unknown, but the 
role of each FcγR in IC-stimulated immune responses is well established by using the gene 
knockout mice.  
Contribution of each FcγR to IgG IC-induced inflammation has been extensively 
examined by using mice genetic deficiency in a variety of FcγRs. FcR-/- mice are 
completely protected from IgG IC-induced ALI when compared with wild type mice (12). 
In addition, it has been demonstrated that genetic depletion of FcγRⅠleads to impaired 
cellular processes induced by IgG IC, including cytokine generation, cellular cytotoxicity, 
phagocytosis, and antigen presentation (13). Moreover, FcγRⅠdeficient mice are resistant 
to hypersensitivity responses, as reflected by decreased cartilage damages in an arthritis 
model (13). Recent studies show that microRNA-127 (miR-127) reduces IgG IC-induced 
ALI by downregulating FcγRⅠexpression (14). When compared with wild type mice, 
FcγRⅢ knockout mice show markedly attenuated inflammatory responses during IgG 
IC-induced alveolitis, with reduced expressions of TNF-α, interleukin( IL)-1, and MIP-2 
(15).  Antibody-induced thrombocytopenia could be prevented by blocking binding of 
FcγRⅣ  to pathogenic antibodies against platelets (7). Blocking FcγRⅣ results in 
decreased phagocytosis and cytokine expressions during IgG IC-induced ALI, though 
augmented expression of FcγRⅣ alone could not trigger the disease in FcγRⅢ knockout 
mice (16). FcγRⅡ deficiency lowers the threshold of IC stimulation of alveolar 
macrophages, as proved by analysis of FcγRⅡknockout macrophages which display 
increased calcium and phagocytosis upon IC challenge (12). FcγRⅡdeficient mice are 
more sensitive to IC-induced pulmonary injury, as reflected by increased neutrophil 
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accumulation, edema, and hemorrhage (12). As mentioned above, both neutrophils and 
alveolar macrophages constitutively express FcγRs. Moreover, it has been demonstrated 
that airway epithelial cells can also express functional FcγRs (17). Thus, to understand the 
role of different FcγR in IgG IC-induced acute lung inflammation in more detail, mice 
selectively depleted of distinct FcγR in neutrophils, lung epithelial cells, and macrophages 
will be useful.  
Roles of C5a Signaling in IgG IC-mediated Inflammation 
Complement is discovered about a century ago as a heat-labile component of 
normal plasma. Activation of complement system plays pivotal roles in innate immune 
defense to eradicate invading microbial pathogens. However, overactivation of 
complement has been reported to lead to many inflammation-related diseases, such as IgG 
immune complex (IC)-induced acute lung injury (18, 19), caecal ligation and puncture 
(CLP)-induced sepsis (20-27), and asthma (28). By now, four pathways have been 
demonstrated to be involved in complement activation—classical pathway, 
mannan-binding lectin pathway, alternative pathway, and coagulation pathway. The 
classical pathway can be activated by direct association of C1q with the microbial 
pathogen surfaces. It can also be initiated by binding of C1q to antigen-antibody 
complexes during an adaptive immune response. Thus, it is a bridge linking innate immune 
responses and adaptive immune responses. The mannan-binding lectin pathway is trigged 
by binding of mannan-binding lectin to carbohydrate structures containing mannose that 
present on bacterium or virus surfaces. The alternative pathway is activated by binding of 
spontaneously activated complement peptide to pathogen surfaces. All three pathways 
described above result in a series of enzymatic cleavage reactions, leading to formation of 
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C3 convertase, at which the three pathways converge. C3 convertase has an important 
effect on complement activation, because it can lead to formation of C3a, C3b, C5a, C5b, 
C6, C7, C8, and C9, among which C5b, C6, C7, C8 and C9 form a membrane attack 
complex (C5b-9), which is used by host to lyse gram-negative bacteria. Coagulation 
pathway is recently identified at Peter A. Ward’s lab at the University of Michigan, and 
they find that thrombin functions as C5 convertase in the absence of C3, leading to 
production of C5a and formation of C5b-9 (18). In addition, tissue factor (TF) and other 
factors may be responsible for thrombin production from prothrombin in C3 knockout 
mice (18). Moreover, most recent study demonstrates that in multiple trauma patients, 
factorⅦ -activating protease (FASP), which is activated by circulating nucleosomes 
released from necrotic cells, interacts with complement proteins in plasma, and cleaves C3 
and C5 to produce C3a and C5a (29). Though complement initiation is necessary for 
appropriate immune reactions, excessive complement activation does harm to hosts. Thus, 
activation of complement system is considered as “double-edge sword”. During IgG 
IC-induced acute lung injury, excessive production of C5a occurs, and its function has 
been extensively investigated.  
 Under inflammatory conditions, C5a can activate signaling cascades in both 
endothelial cells and phagocytic cells. For example, C5a treatment greatly augments 
TNF-α and MIP-2 expressions in alveolar macrophages challenged by IgG IC (30). In 
contrast, in the presence of C5a, lipopolysaccharide (LPS)-induced TNF-α expression in 
neutrophils is significantly reduced, which is mediated by increased levels of nuclear factor 
of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) that can 
suppress nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation 
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(31). In human basophils, C5a is a potent stimulator of plasminogen activator inhibitor-1 
expression (32). In addition, cluster of differentiation molecule 11b/18 (CD11b/CD18) 
expression on neutrophils and eosinophils is significantly increased by C5a, which leads to 
augmented adhesion of both granulocytes to human umbilical vein endothelial cells 
(HUVECs) or human bronchial epithelial cells (HBECs) (33). It has been demonstrated 
that binding of C5a to HUVECs significantly increases P-selectin expression, which is 
required for early adhesive interaction between endothelium and polymorphonuclear 
neutrophils (PMNs) (34). Moreover, intravenous injection of anti-rat C5a antibodies 
almost abrogates lung vascular P-selectin generation during cobra venom factor 
(CVF)-induced acute lung injury, which indicates that C5a is required for pulmonary 
vascular P-selectin expression (35). Recently, cDNA microarray analysis shows that C5a 
treatment markedly increases expressions of cell adhesion molecules in HUVECs, 
including E-selectin, vascular cell adhesion protein 1 (VCAM-1), and (intercellular 
adhesion molecule 1) ICAM-1, which are necessary for transendothelial trafficking of 
neutrophils  (36). In the same study, it is observed that gene expression for cytokines and 
chemokines is also greatly elevated (36). Initial exposure of mouse dermal microvascular 
endothelial cells (MDMECs) to LPS, interferon-gamma (IFN-), or interleukin-6 (IL-6), 
followed by C5a challenge causes synergistic generation of monocyte chemotactic 
protein-1 (MCP-1) and MIP-2, which indicates that C5a in the co-presence of additional 
stimulators could induce strong immune reactions in endothelium (37).   
During IgG IC-induced acute lung inflammation, growing evidence suggests that 
activation of complement system is indispensible for full pulmonary inflammatory 
responses (38). When compared with C5 sufficient mice, C5 deficient mice displays 
 7
reduced edema, hemorrhage, neutrophil accumulation, and wet/dry ratios of lung (a marker 
of lung vascular permeability) after pulmonary deposition of IgG IC, suggesting that  
C5a—a phlogistic fragment of C5, might be involved in IgG IC induced ALI (39). 
Intratracheal instillation of antibodies against C5a markedly inhibits IgG IC-induced 
pulmonary damages by decreasing TNF-α concentration in bronchoalveolar lavage (BAL) 
fluids, lung vascular ICAM-1 expression, pulmonary myeloperoxidase (MPO) activity, 
and lung vascular permeability (40). In contrast, intravenous instillation of anti-C5a 
antibodies has no protective effects against IgG IC-induced ALI, which suggests that IgG 
IC-induced C5a generation in the airway is indispensible for full development of 
pulmonary inflammation (40). Recent studies show that in the presence of activated 
neutrophils or alveolar macrophages, C5a is generated by enzymatic cleavage of C5, which 
means that C5a could be produced in the absence of plasma complement system (41).  It is 
also found that treatment with antibodies to C5a protects mice from intravenous 
administration of CVF-induced lung injury, which indicates that systemic activation of 
complement-mediated lung injury is dependent on C5a (40). Both in vitro and in vivo 
experiments further prove the critical roles of C5a in IgG IC-induced inflammation. In 
vitro studies show that in the presence of anti-C5a antibodies, IgG IC-induced production 
of MIP-2, cytokine-induced neutrophil chemoattractant (CINC), MIP-1α, macrophage 
inflammatory protein 1 beta (MIP-1β), and MCP-1 is greatly reduced in rat alveolar 
macrophages (42). Moreover, treatment with blocking antibody to C5a also significantly 
inhibits generation of the chemokines in the rodent pulmonary model stimulated by IgG IC 
(42). It is further demonstrated that C5 and C5a positively regulate IgG IC-induced severe 
airway hyperreactvity by using mice genetically depleted of C5, and mice receiving 
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blocking antisera to C5a, respectively (43). However, recent data show that systemic 
activation of complement is not observed after airway injection of LPS, and 
immunopathogenesis of LPS-induced experimental ALI is independent of C3, C5, and C5a 
(44). Take together, these data show that during IgG IC-induced ALI, C5a generation 
through activation of complement system is an early event triggering inflammatory 
signaling cascades. 
C5a exerts the biological activity through binding to its receptors—C5a receptor 
(C5aR) and C5a receptor-like 2 (C5L2). C5aR, which is also known as CD88 or 
complement component 5a receptor 1 (C5AR1), is a G-protein-coupled receptor with 
seven transmembrane segments. C5aR has a molecular weight of 45 kDa, and binds to C5a 
with high affinity, to a lesser extent, to C5a des Arg. Originally, it is thought that C5aR is 
exclusively expressed by myeloid cells, such as macrophages, monocytes, neutrophils, 
basophils, and eosinophils (45). Now there are growing evidences that C5aR expression 
could also be found to occur on a variety of nonmyeloid cells, such as bronchial and 
alveolar epithelial cells, smooth muscle cells, Kupffer cells, endothelial cells, astrocytes, 
kidney tubular epithelial cells, and other parenchymal cells of solid organs, including lung, 
kidney, liver, and heart (19).  Treatment of alveolar epithelial cells (AECs) with LPS, 
TNF-α, IL-6, or C5a greatly increases binding of C5a, which is linked to elevated C5aR 
expression (46). Moreover, in the presence of C5a, LPS further augments inflammatory 
responses (46). Exposure of mouse dermal microvascular endothelial cells to LPS, IFN-, 
or IL-6 enhances binding of C5a, which is related to C5aR expression on surfaces of the 
cells (37). Also, IL-6-mediated immune reactions are further increased by C5a in the cells 
(37). Incubation of HUVECs with C5a significantly upregulates expressions of IL-1β, 
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interleukin-8 (IL-8), and regulated and normal T cell expressed and secreted (RANTES) at 
mRNA level (47). However, their expressions are greatly suppressed by treatment of the 
cells with antibodies against C5aR, indicating that interaction between C5a and C5aR is 
required for full production of the proinflammatory mediators (47). Interestingly, IL-6 
generation is downregulated by C5a, which suggests that other signaling pathways 
activated by C5a are responsible for the inhibition of IL-6 expression (47). In vivo studies 
show that gene-targeted disruption of C5aR alleviates IgG IC-induced acute lung injury 
(48). IgG IC-mediated lung inflammation is also attenuated by using competitive C5aR 
antagonist that can inhibit the receptor phosphorylation and ensuing signaling transduction, 
indicating that C5aR is required for inflammatory signaling transduction induced by C5a in 
the model (49).  The strict requirement of FcRs for a variety of IgG IC-mediated immune 
reactions make us hypothesize that inflammatory signaling transduction triggered by 
complement activation is secondary to or independent of FcRs activation (50, 51). 
However, recent studies show that signaling cascades induced by both FcRs and 
complement system are necessary for full immune responses after intratracheal deposition 
of IgG IC in rodents, which suggests that FcRs-induced signaling transduction might be 
integrated through C5a-meidated C5aR activation (10, 15, 30, 50, 51). In vitro data show 
that C5aR activation increases FcγRⅢ expression while decreases FcγRⅡproduction, 
which augments IgG IC-induced TNF-α and MIP-2 generation in alveolar macrophages 
(30). In vivo studies demonstrate that C5aR depletion decreases FcγRⅢ/FcγRⅡratio as 
compared with wild type counterparts, causing reduced inflammatory mediators’ 
generation, neutrophil accumulation, and ensuing lung injury induced by pulmonary 
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deposition of IgG IC (30). Therefore, binding of C5a to C5aR plays an essential role in 
promoting IgG IC-induced ALI by increasing FcγRⅢ/FcγRⅡratio. 
C5L2 is encoded by the GPR77 gene in humans, and has a molecular weight similar 
to C5aR. It belongs to a subfamily of C3a, C5a, and N-formyl-methionyl-leucyl-phenyl- 
alanine (fMLP) receptors, and its expression could be detected in different types of cells, 
such as granulocytes and immature dendritic cells (52). While C5L2 binds to C5a and C5a 
des Arg with high affinity, the interaction between C5L2 and other ligands, such as C3a 
and C3a des Arg, is still a matter of controversy (53-57). Unlike the previously described 
C5aR that is a G-protein-coupled receptor, C5L2 is uncoupled from G-proteins because of 
an amino acid alteration in the so-called DRY region of the third intracellular loop, and the 
association of C5L2 with C5a could not induced transient intracellular calcium influx due 
to the replacement of arginine by leucine in the DRY region (58). In addition, rat C5L2 first 
is cloned by Peter A. Ward group, and its cDNA sequence is 59.8%, and 86.4% identical to 
human C5L2, and mouse C5L2, respectively (59). Hydropathy analysis shows that rat 
C5L2 has seven transmembrane segments (59). C5a binding domain is located at the 
N-terminus of C5L2, and rat C5L2 has the DRY motif in the third intracellular loop, which 
is much shorter than that of C5aR (59). The bulk of C5L2 are located in cytosol in the 
“resting” PMN, which is in striking contrast to C5aR that mainly appears to be on cell 
surfaces (59).  
  First C5L2 knockout mouse is constructed by Craig Gerard group, Harvard 
Medical School, and C5L2 deficiency has no effect on C5aR function, because 1) C5L2 
knockout mice has no influence on C5aR expression, as confirmed by Northern blot assay; 
2) intraperitoneal injection of C5a into wild type and C5L2 deficient mice induced 
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indistinguishable neutrophilic infiltrates (53). However, C5L2 could act as a “decoy” 
receptor, and protect mice from IgG IC-induced acute lung injury. In IgG IC-mediated 
acute lung inflammation model, C5L2 knockout deteriorates inflammatory parameters: 1) 
pulmonary deposition of immune complex leads to greater influx of PMNs in C5L2 
knockout mice when compared with wild type littermates; 2) C5L2 deficient mice express 
significantly more TNF-α and IL-6 in comparison with wild type counterparts; 3) 
histologic analysis of lung lavage and tissue sections show that enhanced inflammation 
occurred in C5L2 knockout mice compared with wild type rodents (53). Though C5L2 is 
reported as a “decoy” receptor, most recent data show that C5L2 could also be a functional 
receptor. In a mouse model of ovalbumin (OVA)- or house dust mite-induced experimental 
allergic asthma, C5L2 deficiency leads to attenuated asthmatic phenotype: 1) decreased 
airway hyperresponsiveness (AHR) and Th2 cytokine (IL-5, IL-13, IL-4, and IL-10) 
expressions are observed in C5L2 knockout mice upon pulmonary exposure to either OVA 
or house dust mite; 2) C5L2 knockout results in reduced lymphocytes accumulation, and 
eosinophils numbers as well as serum IgE level; 3) histologic analysis reveals reduced 
airway inflammatory cells and mucus production (60). Therefore, C5L2 may play different 
roles in distinct disease models. 
Activation of Transcription Factors by IgG IC  
IgG IC-induced FcR aggregation initiates immune response-related signaling 
transduction, which lead to expressions of inflammatory genes encoding cytokines and 
chemokines, such as TNF-α, IL-1, IL-10, MIP-2, CINC, keratinocyte-activated cytokine 
(KC), MIP-1α, MIP-1β, eotaxin, and MCP-1 (10). The expressed genes include both 
proinflammatory and anti-inflammatory mediators, and their relative level determines the 
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inflammatory intensity. The precise mechanisms involved in signaling transduction from 
FcR to cytoplasm and then to nucleus remains largely unknown, but it has been 
demonstrated that several transcription factors including NF-κB, Activator Protein-1 
(AP-1), and Signal Transducer and Activator of Transcription 3 (STAT3) are activated 
during IgG IC-mediated inflammatory response (61-63).  
As transcription factors, NF-κB family is composed of five members: p65 (RelA), 
RelB, c-Rel, p52/p100, and p50/p105, and they share a conserved Rel homology domain 
(RHD), which is consisted of 300 amino acids, and located toward the N-terminus of the 
protein. RHD is required for their DNA binding, activity regulation, and dimerization (64). 
The family members exist in cells by forming homodimers or heterodimers (64). There are 
two pathways involved in NF-κB activation—classical pathway and alternative pathway 
(64). In the classical pathway, inhibitor of nuclear factor kappa-B kinase subunit beta 
(IKKβ) is activated by stimulators, leading to phosphorylation of IκB while in the 
alternative pathway, activated IKKα phosphorylates p100 (64). These two pathways 
converge at proteasomes, leading to release of mature NF-κB dimers that translocate to the 
nucleus and promote transcription of target genes (64, 65). 
A variety of inflammation-related gene expressions, which include cytokines, 
adhesion molcules, and chemokines, are regulated by NF-κB. These inflammatory 
mediators play a critical role in inflammation-induced pulmonary damages. Thus, NF-κB 
activation is an upstream event in the inflammatory cascades, and may be involved in 
regulation of inflammation-induced lung injury. In vivo studies show that pulmonary 
transcription of ICAM-1, E-selectin, P-selectin, VCAM-1 genes follows NF-κB activation 
during endotoxin-induced acute lung injury (66). Furthermore, endotoxin-induced binding 
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of NF-κB to its consensus sequence in E-selectin promoter region, indicating that NF-κB 
directly mediates target genes’ production at transcription level (66). During IgG 
IC-induced ALI, whole lung NF-κB is activated, followed by TNF-α and IL-1β 
expressions (61). In addition, NF-κB DNA binding activity is also enhanced in alveolar 
macrophages by intrapulmonary deposition of IgG IC (61). Now, it has been demonstrated 
that alveolar macrophages are required for intrapulmonary activation of NF-κB in IgG 
IC-induced alveolitis, because alveolar macrophage depletion leads to depressed lung  
NF-κB activity (67). Whole lung NF-κB activation could be restored in alveolar 
macrophage-depleted mice receiving intrapulmonary administration of TNF-α (67).  In the 
model of IgG IC-triggered lung injury, TNF-α plays an essential role in full development 
of acute lung injury by increasing neutrophil accumulation, and is expressed mainly by 
alveolar macrophages as evidenced by immunohistochemical assay of cells recovered from 
BAL fluids and pulmonary sections (67). Therefore, TNF-α expression by IgG 
IC-activated alveolar macrophages is an upstream event in the inflammatory cascades, 
which is required for full activation of NF-κB in other types of cells in the lung, including 
pulmonary vascular endothelium and alveolar epithelial cells. NF-κB activation is also 
regulated by anti-inflammatory mediators, such as IL-10 and IL-13. Both cytokines 
increase IκBα expression at both mRNA and protein levels, which inhibits nuclear 
translocation of NF-κB after intrapulmonary deposition of IgG IC (68). Suppression of 
NF-κB activation in alveolar macrophages and whole lungs results in decreased TNF-α 
expression, leading to reduced neutrophil influx and ensuing lung injury (68).  Thus, both 
proinflammatory and anti-inflammatory pathways converge at NF-κB, and their balance 
determines the intensity of lung damages. Interestingly, both in vitro and in vivo studies 
 14
shows that NF-κB activation is positively regulated by TNF-α and IL-1β,  but C5a has no 
effect on its activity-induced by IgG IC, which suggests that C5a-mediated inflammation 
might be involved in other transcription factors (61).  
It has been proved that reactive oxygen species (ROS) are produced by neutrophils 
and macrophages during stimulation by various agents or phagocytosis, and are promoters 
of NF-κB activation (69, 70). NF-κB activity is significantly reduced in p47phox deficient 
mice when compared with wild type mice during endotoxin-induced ALI (71). p47phox is 
the cytosolic subunit of the multi-protein complex known as NADPH (Nicotinamide 
Adenine Dinucleotide Phosphate, reduced) oxidase that is responsible for ROS generation. 
Therefore, NF-κB activation is positively regulated by ROS in the model. In IgG 
IC-induced ALI, NF-κB activation is greatly impaired in mice receiving N-acetylcysteine 
(NAC), but not catalase that could not penetrate cell membrane due to its large molecular 
weight, indicating that it is intracellular but not extracellular ROS play an important role in 
pulmonary NF-κB activation (61). In addition, IgG IC-induced NF-κB activation is 
independent of neutrophils, thus, intracellular ROS produced by alveolar macrophages are 
responsible for partial pulmonary NF-κB activation (61). Recent data show that NAC 
treatment downregulates NF-κB activation by impairing interaction of TNF-α with its 
receptor but not ROS generation (72). Thus, to further examine the role NF-κB activation 
mediated by ROS, p47phox knockout mice should be used in the IgG IC model of lung 
injury. Furthermore, in the endotoxin-induced ALI model, ROS has no effect on 
pulmonary inflammation and ensuing lung injury, thus, more effects should be made to 
investigate the role of ROS themselves in IgG IC-mediated pulmonary damages (71).  
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 AP-1 are transcription factors, and exist in the cells as homodimers or heterodimers 
composed of proteins that belong to Fos, Jun, and activating transcription factor (ATF) 
families (73). AP-1 could be activated by a variety of stimuli, such as ROS, DNA damage, 
and proinflammatory cytokines (eg, TNF-α, and transforming growth factor-β) (10, 63, 
74-76) .  Activated AP-1 play an important role in cellular differentiation, proliferation, 
apoptosis, and transformation (10, 75). However, its effect on lung inflammation remains 
largely unknown. Transcription of many inflammation-related genes, especially those 
encoding chemokines and cytokines is dependent on binding of AP-1 to the consensus 
sequences in their promoter regions, which indicates that AP-1 activation might be 
involved in inflammatory diseases (77-79).  AP-1 is activated during endotoxin-induced 
ALI (80, 81). Additionally, AP-1 overexpression is observed in lungs of smokers (82). In a 
rat model of lung fibrosis, AP-1 activation is induced in lungs after airway instillation of 
bleomycine due to augmented expression of c-Jun and c-Fos in alveolar macrophages and 
typeⅡlung epithelial cells (83). In asthmatic patients, c-Fos expression is increased in 
epithelial cells (84). Corticosteroid-treated patients rarely express c-Fos, which suggests 
that AP-1 play an essential role in inflammatory reactions in asthma (84). During IgG 
IC-induced ALI, AP-1 activation is observed in both alveolar macrophages and whole 
lungs, which is due to increased expressions of c-Fos, c-Jun, Jun-B, and Jun-D (63). 
Moreover, IgG IC-induced pulmonary AP-1 activation is dependent on alveolar 
macrophages, because AP-1 activity is sharply reduced in alveolar macrophage-depleted 
mice (63). Furthermore, TNF-α but not C5a is required for full activation of AP-1 in IgG 
IC-challenged lungs (63). More studies will be needed to determine the role of AP-1 in IgG 
IC-mediated pulmonary injury, and the contribution of neutrophils and IgG IC-induced 
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ROS to AP-1 activation. Also, extensive experiments should be performed to investigate 
whether there is cooperation between AP-1 and NF-κB during IgG IC-induced 
inflammation responses, because the cooperation is necessary for the maximal expressions 
of various inflammation-related genes (85). 
 Signal Transducer and Activator of Transcription 3 (STAT3) belongs to STAT 
protein family that is composed of seven members—STAT1, STAT2, STAT3, STAT4, 
STAT5A, STAT5B, and STAT6. STAT proteins are activated in response to a variety 
stimuli, including cytokines, and growth factors. STAT3 is first described in hepatocytes as 
a transcription factor, and capable of binding to the acute-phase response element in the 
promoter regions, leading to transcription of acute-phase genes (86-90). STAT3 activation 
is initiated by ligand-induced receptor dimerization, followed by activation of 
receptor-associated Janus kinase (JAK), which leads to STAT3 phosphorylation. 
Phosphorylation induces dimerization, and subsequent nuclear translocation, resulting in 
transcription of target genes (91). STAT3 knockout mice die during embryonic 
development, but studies from tissue or cell-specific depletion of the STAT3 gene have 
indicated that STAT3 might be involved in inflammatory reactions (92, 93). When 
compared with wild type littermates, mice selectively depleted of STAT3 in respiratory 
epithelial cells are more susceptible to hyperoxia-induced acute lung injury, which is 
linked to lung microvascular permeability and acute respiratory distress (94). In STAT3 
deficient mice, a more rapidly progressive epithelial cell injury and inflammatory reactions 
are observed during hyperoxia-mediated ALI (94). However, intratracheal administration 
of surfactant protein B could attenuate features of lung injury and improve survival rates in 
STAT3 knockout mice, indicating STAT3-regulated expression of surfactant protein B at 
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transcription level protects mice from hyperoxia-induced ALI (94, 95). Additionally, in 
LPS-induced ALI, conditional depletion of STAT3 in respiratory epithelial cells in the 
lung results in decreased surfactant lipid synthesis, leading to increased inflammatory 
mediators’ production and vascular permeability (96).  Human beings with 
dominant-negative mutations in the STAT3 gene develop recurrent pulmonary infections, 
indicating that STAT3 plays an essential role in host defense against the lung infection (97). 
During Escherichia coli-induced pneumonias, mice selectively depleted of STAT3 in lung 
epithelial cells are more sensitive to Escherichia coli infection, evidenced by fewer 
neutrophil accumulation and more viable bacterial load (97).  Furthermore, IL-6 and 
leukemia inhibitory factor-activated STAT3 in lung epithelial cells is indispensible for 
recruitment of neutrophils into lungs (97). Taken together, the above data show that 
STAT3 activation in lung epithelial cells inhibits acute pulmonary inflammation. A recent 
study displays that overexpression of suppressor of cytokine signaling 3 (SOCS3) in lung 
epithelial cells leads to increased production of proinflammatory mediators, and 
recruitment of neutrophils into lung interstitial and alveolar compartments, and ensuing 
exacerbated lung damages, which indicates a negative feedback regulation of JAK-STAT3 
signaling cascades by SOCS3 (98).  
During IgG IC-induced ALI, STAT3 are activated in alveolar macrophages, as well 
as whole lungs (62). IgG IC-mediated whole lung STAT3 activation is dependent on 
neutrophils and alveolar macrophages, because depletion of either neutrophils or alveolar 
macrophages significantly impairs its activation (62). Unlike NF-κB and AP-1, C5a are 
required for full activation of STAT3 in the lung (62). Interestingly, both IL-6 and IL-10 
are necessary for the maximal activation of STAT3 (62). IL-6 is a proinflammatory 
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cytokine while IL-10 is an anti-inflammatory cytokine, indicating that STAT3 may 
participate in both proinflammatory and anti-inflammatory reactions during IgG 
IC-mediated ALI. Recent data show that in the presence of LPS, IL-6-induced STAT3 
activation is greatly impaired by upregulated SOCS3 expression whereas IL-10-mediated 
STAT3 activation is not affected by SOCS3, and in the absence of SOCS3, IL-6 
participates in anti-inflammatory responses by increased STAT3 activation (99). Because 
intrapulmonary deposition of IgG IC significantly induces SOCS3 expression, leading to 
reduced STAT3 activation mediated by IL-6, IL-6-induced STAT3 activation promotes 
IgG IC-stimulated inflammation (98). Our in vitro data demonstrate that STAT3 plays an 
important role in IgG IC-induced inflammatory responses by promoting proinflammatory 
mediators’ generation in alveolar macrophages (93). Moreover, our in vivo studies further 
prove that knock down of STAT3 leads to reduced production of inflammatory mediators, 
pulmonary microvascular permeability, neutrophil accumulation, and ensuing lung injury 
after pulmonary deposition of IgG IC (93).  Therefore, the exact role of STAT3 in 
pulmonary inflammation is dependent on specific diseases. By now, four different 
isoforms of STAT3 have been defined: STAT3α, STAT3β, STAT3, and STAT3δ (100, 
101). Thus, more studies should be performed to investigate the individual activity of those 
four STAT3 isoforms during IgG IC-mediated ALI, and examine their relative 
contribution to inflammation and ensuing lung injury.   
Roles of CCAAT/Enhancer-binding Proteins in Inflammation 
CCAAT/enhancer-binding protein (C/EBP) family consists of six members: 
C/EBPα, β, γ, δ, ε, and ξ, which belong to basic region-leucine zipper (bZIP) transcription 
factors (102). The bZIP domain is located in a conserved sequence in the C-terminal 55-56 
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amino acid residues (103). In contrast to the bZIP domain in the conserved C-termini, the 
sequence identity in the N-termini of C/EBP proteins is less than 20%, which determines 
their different roles in transcription (103). bZIP domain contains a DNA binding region 
that is rich of basic amino acids, which is followed by the“leucine zipper” that is 
responsible for dimerization (104-116). C/EBP proteins exist in cells as homodimers or 
heterodimers, and the formation of heterodimers between different C/EBP proteins is due 
to the highly conserved bZIP domain. The C/EBP proteins interact with a consensus DNA 
sequences: 5’-T(T/G)NNGNAA(T/G)-3’, and play roles in transcriptional activation or 
repression via the N-terminal domains (105, 107, 109, 117, 118). However, C/EBPξ is an 
exception, because it cannot bind to the identical recognition sequence as other family 
members due to the two proline residues in the basic region which prevent the formation of 
α-helical conformation (116). Because of the intact leucine zipper, C/EBPξ can still form 
heterodimers with other family members, and inhibit the regulation of target gene 
transcription by other C/EBP proteins. However, the heterodimers formed by C/EBPξ and 
other C/EBP proteins could bind to the promoter regions of various cellular 
stress-regulated genes, and promote their transcription (119).   Thus, C/EBPξ might 
function as both transcriptional promoter and inhibitor, which is dependent on the stimuli. 
The in vitro binding activities of these C/EBP family members are almost the same, 
however, the diversity of C/EBP family members and their potential for forming different 
heterodimers can provide a large pool of transcription factors with complicated regulatory 
functions in vivo. All C/EBP family members could participate in inflammation by 
exerting influence on myeloid development or inflammation-related cytokine production, 
and play important roles in pulmonary diseases. 
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There are two C/EBPα isoforms—full-length C/EBPα with a molecular weight of 
42 kDa (p42C/EBPα) and p30C/EBPα (30 kDa) (120). p30C/EBPα is produced by 
alternative use of translation initiation codons (120). C/EBPα is an important regulator of 
myeloid lineage commitment. This is because C/EBPα knock out newborn mice show a 
defect in differentiation of neutrophils, which is due to loss of the granulocyte 
colony-stimulating factor receptor’s expression positively regulated by C/EBPα (121). 
However, it is found that the phenotype in C/EBPα deficient mice is different from that of 
granulocyte colony-stimulating factor receptor knockout mice, which suggests that other 
gene expressions that are involved in granulopoiesis are regulated by C/EBPα. It is 
demonstrated that expressions of IL-6 receptor and IL-6-responsive colony-forming unites, 
which contribute to granulopoiesis, are abrogated in mice depleted of C/EBPα (122).  
Interestingly, blocking of granulocyte colony-stimulating factor signaling has no effect on 
differentiation of macrophages (121). In adult mice, deleted C/EBPα in bone marrow 
thwarts the transition of the common myeloid progenitor to granulocyte-monocyte 
progenitor, thus, bone marrow is filled with myeloblasts, which is similar to human acute 
leukemia (123). In addition, deletion of C/EBPα in hematopoietic progenitor cells 
demonstrates hyperproliferation of the cells and inability of multipotential progenitors to 
differentiate into granulocyte/macrophage progenitors, leading to markedly diminished 
macrophages and neutrophils (124). All the myeloid development processes as mentioned 
above are involved in C/EBPα-induced PU.1 expression and interaction of C/EBPα with 
AP-1 and NF-κB (125). 
C/EBPα, C/EBPβ and C/EBPδ expressions could be detected in bone 
marrow-derived macrophages (126). In the presence of LPS, DNA binding activity of both 
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C/EBPβ and C/EBPδ is increased while that of C/EBPα is reduced, indicating that 
C/EBPβ/C/EBPδ, and C/EBPα may have different role in inflammatory responses (126). 
Knockdown of C/EBPα significantly reduces IL-6 and TNF-α expressions in macrophages 
treated with LPS (127). In P388 lymphoblasts, ectopic expression of any C/EBP protein is 
sufficient to confer LPS-stimulated production of MCP-1 and IL-6 to the lymphoblasts 
(126). Because these lymphoblasts do not express C/EBP proteins, and are unresponsive to 
LPS treatment, the activities of C/EBPα, C/EBPβ and C/EBPδ are redundant, indicating 
that lack of C/EBPβ/C/EBPδ could be compensated by C/EBPα expression under certain 
inflammatory conditions (126). Upon infection and/or tissue damage, an inflammatory 
reaction called acute phase response is induced. During the acute phase response induced 
by intraperitoneal injection of LPS, expression of C/EBP family members is dramatically 
altered (128). C/EBPα production is significantly reduced while C/EBPβ and C/EBPδ 
expressions are markedly increased in the lung, indicating that C/EBP family members 
might be involved in regulation of acute phase gene expressions in lungs (128). Among the 
C/EBP family members, C/EBPβ and C/EBPδ are thought to function as the major 
stimulators of acute phase response (129). Further studies show that C/EBPα is also 
involved in the inflammatory process (129). Neonatal mice lacking C/EBPα is completely 
resistant to LPS- or IL-1β-mediated acute phase response when compared with wild type 
littermates, though compensatory increase of both C/EBPβ and C/EBPδ DNA binding 
activities is obvious in C/EBPα null mice (129). Thus, C/EBPα is indispensible for acute 
phase response in neonatal mice. C/EBP family members exist in cells as homodimers or 
heterodimers, the absolute requirement of C/EBPα for acute phase response might be 
explained by the essential roles of C/EBPα:C/EBPβ heterodimer and C/EBPα:C/EBPδ 
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heterodimer in the inflammatory process (129). In addition, in C/EBPα null mice, STAT3 
DNA binding are not activated in response to LPS, indicating that C/EBPα-mediated 
STAT3 activation might be important for acute phase response (129).   
Though C/EBPα null mice die shortly after birth, the role of C/EBPα during 
postnatal development has not been elucidated. Recent studies show that mice die about 30 
days after total depletion of C/EBPα during postnatal development due to abnormal change 
in metabolic processes (130). C/EBPα deficient in lung epithelial cells also leads to about 
56% death within hours after birth because of respiratory distress (131). The survival mice 
develop a severe pathological pattern similar to chronic obstructive pulmonary disease 
(COPD) (131). Pulmonary histological assay of C/EBPα knockout mice demonstrates that 
type Ⅱ lung epithelial cells undergo hyperproliferaion and alveolar architecture is 
disturbed, which suggests an essential role for C/EBPα in lung development (132). To 
understand the role of C/EBPα in lungs, use of siRNA targeting C/EBPα is an acceptable 
method. Exposure of newborn mice to 95% oxygen leads to enhanced C/EBPα expression 
which is primarily derived from type Ⅱlung epithelial cells (133). Although hyperoxia 
results in increased differentiation and expression of markers for typeⅠlung epithelial 
cells, C/EBPα-specific siRNA treatment alleviates these hyperoxic features with an 
exception of lung morphologic change (133).   Nevertheless, lung morphology is restored 
in C/EBPα siRNA-, but not control siRNA-treated mice after 2-week recovery in normal 
air, which suggests that C/EBPα expression in type Ⅱlung epithelial cells is responsible 
for cell proliferation and differentiation during pulmonary damage and repair (133). 
Pulmonary abnormalities are not observed in the transgenic mice, in which C/EBPα is 
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genetically depleted from Clara cells and type Ⅱlung epithelial cells after birth, indicating 
that C/EBPα is critical for early pulmonary development but not required for maintenance 
of lung architecture after birth (96). When compared with wild type adult mice, the 
transgenic mice are more susceptible to hyperoxia-induced ALI, which is due to severe 
pulmonary inflammatory responses, abnormal pulmonary mechanics, reduced mature 
surfactant protein B and C, and decreased surfactant lipids (96). Overall, C/EBPα plays 
different roles in newborn and adult mice during hyperoxia-induced ALI. Whereas 
newborn mice benefit from downregulation of C/EBPα expression, adult mice benefit from 
upregulation of C/EBPα expression, indicating that specific tissue levels of C/EBPα induce 
beneficial or detrimental effects (133). Immunohistochemistry staining shows that 
expression of C/EBPα could be found in alveolar macrophages and type Ⅱlung epithelial 
cells (134). During bleomycin-induced pulmonary fibrosis, C/EBPα expression is 
significantly induced in some of alveolar epithelial cells and fibroblasts in the fibrotic 
lesions (134). C/EBPα is involved in proliferation of type Ⅱlung epithelial cells and 
expressions of surfactant proteins, including surfactant A, B, and C (135). Lung specific 
deletion of C/EBPα leads to increased generation of surfactant proteins and 
hyperproliferation of alveolar type Ⅱ cells (135). Thus, bleomycin-induced upregulation 
of C/EBPα expression in alveolar epithelium and fibroblasts might be considered as an 
endogenous anti-fibrotic factor. In LPS-treated lungs, C/EBPα expression is also 
significantly increased, indicating that  C/EBPα may have a proinflammatory effect  due to 
its inhibitory influence on generation of surfactant proteins B that is necessary for 
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suppression of LPS-mediated lung injury (134, 136). Overall, C/EBPα can function as a 
disease suppressor or stimulator, which is dependent on specific diseases.  
 C/EBPβ can give rise to three polypeptides, 38 kDa [liver-enriched transcriptional 
activator protein* (LAP*)], 35 kDa (LAP), and 20 kDa [liver-enriched inhibitory protein 
(LIP)], among which LAP and LIP are the major C/EBPβ isoforms found in the cells (137).  
The three different isoforms of C/EBPβ could be generated from the same mRNA by 
alternative use of translation initiation codons (137). LAP contains both transactivation 
domain and bZIP domain, thus, it can act as a transcription stimulator (137). bZIP domain 
but not activation domain is present in LIP, therefore, it could function as a transcription 
repressor by forming homodimers or heterodimers with other C/EBP family proteins (137). 
The function of C/EBPβ has been extensively investigated, and its main role is implicated 
in the regulation of proinflammatory mediators’ production induced by ligands of Toll-like 
receptors (TLRs), IL-1, and IL-6 (109, 110, 138). C/EBPβ plays an essential role in heat 
shock protein 60-induced cyclooxygenase-2 expression in macrophages, as well as 
endothelial cells. Because heat shock protein 60 is an endogenous ligand of TLR4, C/EBPβ 
links TLR4 activation to inflammatory mediator’s expression (139). Many gene promoter 
regions contain C/EBPβ binding site. For example, it has been shown that the activity of a 
reporter gene controlled by IL-6 promoter is greatly stimulated by C/EBPβ (138). All 
functions of C/EBPβ discussed above focus on its role in boosting proinflammatory 
responses; however, evidence has shown that the C/EBP family protein is also dedicated to 
suppression of inflammatory reactions. For example, cooperation between Sp1 and 
C/EBPβ can mediate the IL-10 gene expression in mouse macrophage RAW264.7 
challenged with LPS (140). C/EBPβ inhibits expressions of inflammatory mediators in 
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TNF tolerant monocytes by interacting with NF-κB p65 and preventing its phosphorylation 
(141). In addition, the expression of Clara cell secretory protein (CCSP) that has 
anti-oxidant effects is inhibited by hyperoxia, which is mediated, at least in part, at 
transcription level by increased expression of LIP (142). To investigate the in vivo role of 
C/EBPβ, mice depleted of C/EBPβ are generated.  When compared with wild type mice, 
C/EBPβ knockout mice are more sensitive to infection by Listeria monocytogenes due to 
defect in macrophage bactericidal activity (143). However, TNF and IFN- expressions are 
not impaired in C/EBPβ deficient mice, indicating that the role of C/EBPβ in cytokine 
expression might be compensated by other C/EBP proteins, such as C/EBPα and C/EBPε 
(143). 
Higher C/EBPβ expression is found in the fibrotic lesions during 
bleomycin-induced pulmonary fibrosis (134). In vitro studies show that C/EBPβ plays an 
important role in myofibroblast differentiation, indicating that C/EBPβ might be a key 
regulator of fibrosis (144). In vivo data demonstrate that C/EBPβ knockout leads to 
decreased collagen deposition and fibrotic lesions in the lung during bleomycin-induced 
pulmonary fibrosis (144).  Further studies on mechanisms by which knockout of C/EBPβ 
attenuates fibrosis suggest that when compared with C/EBPβ deficient mice, the wild type 
counterparts express more inflammatory mediators after intratracheal instillation of 
bleomycin (144). In addition, pulmonary fibroblasts lacking C/EBPβ generate less 
α-smooth muscle actin, indicating that myofibroblast differentiation is positively regulated 
by C/EBPβ (144). Moreover, pulmonary fibroblasts isolated from wild type mice display 
less proliferative rates than those from C/EBPβ-/- mice. Overall, C/EBPβ plays 
multifactorial roles in lung fibrosis by regulating inflammatory mediators’ production, 
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fibroblast proliferation, and differentiation (144). Although C/EBPβ knockout protects 
against bleomycin-induced pulmonary fibrosis, the molecular mechanisms by which 
C/EBPβ positively regulates fibrosis remain largely unknown. Recent studies demonstrate 
that C/EBPβ carrying a single point mutation (Thr217 to Ala217) can block 
phosphorylation of C/EBPβ on Thr217 by ribosomal S-6 kinase (RSK), leading to 
attenuated pulmonary injury and fibrosis induced by intratracheal administration of 
bleomycin (145). In addition, in vitro studies find that ERK1/2 is an upstream stimulator of 
RSK, and is required for phosphorylation of C/EBPβ on Thr217 (145). Phosphorylated 
C/EBPβ is associated with procaspase 8, leading to inactivation of the apoptotic pathway in 
pulmonary fibroblasts (145). Moreover, in human patients, phosphorylation of C/EBPβ on 
Thr266 (identical to mouse phosphoacceptor Thr217) is observed in activated pulmonary 
fibroblasts, which could not be detected in control groups, indicating that the signaling 
pathway—ERK1/2-RSK-C/EBPβ, which can prevent fibroblast from apoptosis, might be 
involved in human pulmonary fibrosis (145). Interestingly, a block peptide, which can 
suppress phosphorylation of C/EBPβ on Thr217, alleviates bleomycin-mediated 
pulmonary fibrosis, indicating its possible clinical applications (145). In vitro data show 
that different C/EBPβ isoforms may have distinct roles in fibrosis. IL-1β suppresses 
α-smooth muscle actin in rat lung fibroblasts by increasing the ratio of LIP to LAP (146). 
LIP-mediated inhibition of α-smooth muscle actin expression is initiated at transcription 
level due to its ability to binding to the consensus sequence in the α-smooth muscle actin 
promoter region (146). However, LAP is a stimulator of α-smooth muscle actin expression, 
because α-smooth muscle actin is elevated by ectopic expression of LAP while reduced by 
knockout of C/EBPβ (146).   Further studies on mechanisms by which IL-1β augments LIP 
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expression suggest that IL-1β treatment induces the generation of eukaryotic initiation 
factor 4E that plays a critical role in LIP expression (146). Immunohistochemistry staining 
shows that expression of C/EBPβ could be found in alveolar macrophages and type Ⅱlung 
epithelial cells (134). In LPS-challenged lungs, C/EBPβ expression is found in alveolar 
macrophages, alveolar epithelium, and other inflammatory cells (134). When compared 
with wild type mice, mice with lung specific depletion of C/EBPβ express less KC in 
response to intratracheal administration of LPS, leading to reduced recruitment of 
neutrophils into lungs (147). Therefore, C/EBPβ expression in lung epithelial cells 
contributes to LPS-induced acute lung inflammation by increasing neutrophil influx. 
However, C/EBPβ is also necessary for anti-inflammatory responses induced by 
formoterol—a β2-adrenergic agonist, because inhibition of LPS-mediated neutrophilia by 
formoterol is alleviated in mice lacking C/EBPβ in pulmonary epithelial cells by increasing 
KC production (147). The proinflammatory and anti-inflammatory effects of C/EBPβ 
might be explained by preferential expressions of different C/EBPβ isoforms induced by 
different stimulants. LPS treatment may induce expression of LAP—a transcription 
stimulator, while formoterol preferentially promotes expression of LIP, which is a 
repressor of transcription due to its lacking of transactivation domain located in 
N-terminus.  
The role of C/EBPδ in inflammatory responses has also been investigated. Many 
gene promoter regions contain C/EBPδ binding sites. For example, it has been shown that 
the activity of a reporter gene controlled by IL-6 promoter is greatly stimulated by C/EBPδ 
(148). In addition, LPS-induced binding of C/EBPδ to the consensus sequence is 
indispensible for cyclooxygenase-2 transcription in macrophages (149). However, 
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evidence has shown that C/EBPδ is also involved in anti-inflammatory mediators’ 
generation. For example, C/EBPδ expression is significantly increased in β-cells and 
human islets incubated with IL-1β and IFN-, leading to decreased production of 
chemokines in β-cells. In the lungs, immunohistochemistry staining shows that C/EBPδ 
expression is restricted to some of type Ⅱlung epithelial cells in a spatial pattern in the 
normal lung (134).  Intensive expression of C/EBPδ is observed in some of alveolar and 
bronchiolar epithelium in the fibrotic lesions during bleomycin-induced pulmonary 
fibrosis (134). In LPS-challenged lungs, higher C/EBPδ expression is found in 
proliferating alveolar and bronchiolar epithelial cells (134). C/EBPδ expression is 
significantly increased during differentiation of human feta lung in culture, and is mainly 
produced by alveolar epithelial cells (150). Moreover, its production can be induced by 
cyclic adenosine 3', 5'-monophosphate (cAMP) and glucocorticoids (150). Glucocorticoids 
play an important role in pulmonary development and maturation by regulating different 
gene expressions, among which P450-enzyme CYP2B1 synthesis is significantly induced 
by glucocorticoids in lung epithelial cells (151). Further studies show that glucocorticoids 
induce its expression by enhancing binding of C/EBPβ and C/EBPδ to its promoter region 
(151). In addition, C/EBPδ induced-Clara cell secretory protein (CCSP) expression in lung 
epithelial cells is also involved in binding of C/EBPδ to its consensus sequence in the 
proximal CCSP promoter (151, 152). Furthermore, it is found that in pulmonary epithelium, 
C/EBPδ preferentially interacts with C/EBPα to form heterodimers that can superinduce 
the gene expression driven by CCSP promoter (152). Secretoglobin 3A2, a secreted protein 
with small molecular weight, is primarily generated in lung airways, and its transcription is 
also dependent on C/EBPα and C/EBPδ (153).  
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C/EBPδ expression is significantly induced in lungs and kidneys at both mRNA 
and protein levels during endotoxin-induced disseminated intravascular coagulation (DIC), 
indicating that C/EBPδ might play a role in DIC (154). Further studies demonstrate that 
C/EBPδ knockout partially protects mice from DIC-mediated death by downregulation of 
systematic inflammation, as evidenced by decreased TNF-α and IL-6 levels in circulation 
(154). In addition, DIC-induced kidney injury is impaired in C/EBPδ deficient mice (154). 
Moreover, ischemia/reperfusion-induced acute kidney injury is also alleviated in C/EBPδ 
knockout mice, indicating that C/EBPδ plays an essential role in inflammation-related 
acute kidney injury (154). However, DIC-induced liver injury is exacerbated in C/EBPδ 
null mice, which suggests that C/EBPδ plays different roles in distinct organs, and explains 
the partially protective effect of C/EBPδ during LPS-induced DIC (154).  
C/EBPε expression is restricted to lymphocytes and myeloid cells including 
macrophages and granulocytes (155-157). C/EBPε can give rise to four polypeptides with 
molecular weight of 32 kDa, 30 kDa, 27 kDa, and 14 kDa, respectively. The four different 
isoforms of C/EBPε could be produced by differential splicing and use of two alternative 
promoters (157, 158). 32 kDa and 30 kDa forms contain both transactivation domain and 
bZIP domain, thus, they can act as transcription stimulators (157, 158). bZIP domain but 
not activation domain is present in 14 kDa form, therefore, it could function as a 
transcription repressor (157, 158).  
C/EBPε is an important regulator of myeloid lineage commitment. 
Morphologically, macrophages lacking C/EBPε expression is immature (159). 
Additionally, C/EBPε deficient macrophages show reduced expression of macrophage 
markers, and defect in phagocytic function due to decreased uptake of opsonized yeast 
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when compared with wild type macrophages (159). Analysis of different gene expression 
profiles between wild type and C/EBPε knockout macrophages demonstrates that a subset 
of gene expressions related to inflammatory reaction and differentiation are significantly 
reduced in C/EBPε deficient macrophages (159). Overall, as a transcription factor, C/EBPε 
is necessary for macrophage development and subsequent normal functions in 
inflammation. C/EBPε null mice develope normally but are susceptible to opportunistic 
infections by 3-5 months of age due to lack of functional neutrophils, indicating that 
C/EBPε is required for terminal differentiation and functional maturation of granulocyte 
progenitor cells (160, 161). In vivo studies demonstrate that neutrophils deficient in 
C/EBPε show reduced bactericidal activities due to defect in uptake of opsonized bacteria 
as well as generation of secondary granule proteins (161). In addition, decreased 
recruitment of C/EBPε deficient neutrophils into the local inflammatory site is observed, 
which is because of abnormal expressions of L-selectin and CD11b integrin on PMNs 
(161). Moreover, C/EBPε deficient neutrophils display different cytokine expression 
profile when compared with wild type neutrophils in response to inflammatory stimulation, 
as evidenced by reduced production of interleukin-1 receptor antagonist (IL-1Ra) but 
augmented expression of TNF-α (161). Interestingly, spontaneous expression of TNF-α is 
also elevated in neutrophils deleted of C/EBPε, indicating the C/EBPε might be involved in 
autoimmune diseases (161). Overall, the normal functions are severally impaired in 
C/EBPε knockout neutrophils, leading to the abnormal immune reactions to inflammatory 
challenges. Therefore, C/EBPε is necessary for generation of functional macrophages and 
neutrophils, which is important for host defense against infections.  
 31
To examine if C/EBPβ and C/EBPε could be compensated for each other, double 
knockout mice are constructed. Though C/EBPβ and C/EBPε double knockout mice are 
smaller than single deficient and wile type mice, morphological assay shows that lungs are 
normally developed in the double knockout mice (162). However, mice deficient in 
C/EBPβ and C/EBPε are sensitive to fatal infections and die with 2-3 months due to 
defective differentiation of neutrophils (162). Furthermore, cDNA microarray analysis 
demonstrates that LPS- and IFNγ-induced gene expressions involved in immune reactions 
are inhibited in bone marrow-derived macrophages from the double knockout mice when 
compared those from the single knockout mice (162). Taken together, both C/EBPβ and 
C/EBPε are important for innate immune responses, and could be partially compensated 
for each other in the single knockout mice. 
C/EBPγ is an ubiquitously expressed member of the C/EBP family. It contains a 
C/EBP-like bZIP region; however, it lacks an amino terminal transactivation domain (163, 
164). Consistent with the truncated structure, it has been considered as a “buffer” for 
C/EBP activator (164). Therefore, it can counteract transcriptional activation of other 
C/EBP family members such as C/EBPα or C/EBPβ (164). For example, C/EBPγ represses 
C/EBPβ-mediated human immunodeficiency virus (HIV)-1 long terminal repeat-driven 
transcription in human brain cells (165). Ethanol induction of class Ⅰ alcohol 
dehydrogenase expression in the rat requires binding of C/EBPβ to its consensus site in the 
promoter region, which is inhibited by C/EBPγ (166). In reporter assays, it has been 
demonstrated that C/EBPδ cooperates with EKLF-a CACC-box binding protein, to 
enhance the beta-globin promoter-driven reporter gene expression, while C/EBPγ inhibits 
the transcription activity of EKLF (167). In contrast to the notion of C/EBPγ as an inhibitor, 
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C/EBPγ is also characterized as an activator in recent studies. C/EBPγ is involved in the 
transcriptional upregulation of beta-globin gene in murine erythroleukemia cells (168). 
C/EBPγ is also a positive regulator of IFN-γ expression in splenocytes and natural killer 
(NK) cells (169), and gamma-globin in fetal liver (170). Furthermore, it has been reported 
that C/EBPγ inhibits reporter gene expression in L cell fibroblasts, but it is an ineffective 
repressor in HepG2 hepatoma cells, demonstrating that C/EBPγ modulates gene 
expression in a cell-specific manner (171). Taken together, these findings indicate that 
C/EBPγ has complex effects on gene transcription, and its role remains enigmatic.  
The role of C/EBPγ in inflammation is largely unknown. Previous study suggests 
that C/EBPγ dramatically enhances the activity of C/EBPβ in LPS-mediated IL-6 
promoter-driven reporter gene expression in a B lymphoblast cell line (102). Recently, we 
find that C/EBPγ expression is induced by IL-1β in alveolar type Ⅱ cells, and contributes 
to the inhibition of IL-1β-mediated IL-6 production (172). Further, we demonstrate that 
C/EBPγ inhibits IL-6 expression by forming homodimers that compete with 
C/EBPβ:C/EBPγ heterodimers to bind to the consensus sequence in the IL-6 promoter 
region (172). However, the binding of NF-κB to IL-6 promoter region is not impaired by 
C/EBPγ (172). The data indicate that C/EBPγ suppresses IL-1β-induced IL-6 expression in 
alveolar type Ⅱ cells by inhibiting C/EBPβ:C/EBPγ heterodimers but not NF-κB binding 
to the IL-6 promoter region (172).  
C/EBPζ, also known as C/EBP homologous protein (CHOP), is induced in 
response to endoplasmic reticulum (ER) stress. In airway epithelial cells, LPS-induced 
CHOP expression is positively regulated by MUC5AC. Knockdown of MUC5AC 
significantly reduces CHOP production and protects against ER stress-induced apoptosis. 
 33
Mice receiving intratracheal injection of LPS express higher level of mRNAs for CHOP 
when compared with control mice, which suggests that ER stress-induced CHOP 
expression might play a critical role in LPS-mediated ALI (173). Indeed, in vivo studies 
show that LPS-induced acute pulmonary inflammation is attenuated in CHOP deficient 
mice, as evidenced by reduced mature IL-1β level and neutrophil accumulation (173). 
Further studies demonstrate that CHOP is indispensible for LPS-induced caspase-11, 
which is necessary for activation of pro-IL-1β (173). Overall, CHOP positively regulates 
LPS-induced pathogenesis of pulmonary inflammation by inducing caspase-11 expression. 
During LPS-induced acute endotoxemia, C/EBP activation is evident only in alveolar 
epithelial type Ⅱcells (174). CHOP expression is significantly increased due to elevated 
activating transcription factor 3 and X-box binding protein 1 levels, suggesting that CHOP 
might play an essential role in endotoxin-induced septic shock (175). Furthermore, in vitro 
studies show that overexpression of CHOP induces apoptosis in lung cells, and in vivo data 
demonstrate that CHOP is required for apoptotic death of lung cells during LPS-induced 
septic shock, indicating that ER stress-induced CHOP expression plays an essential role in 
lung pathogenesis (175). The molecular mechanisms underlying idiopathic pulmonary 
fibrosis (IPF) are largely unknown. Recent data show that CHOP expression is 
significantly induced in the whole lung and alveolar epithelial type Ⅱcells, leading to 
expression of proapoptotic, oligomeric forms of Bcl-2–associated X (Bax) protein that 
accelerates apoptosis of alveolar epithelial type Ⅱcells and development of fibrosis in 
patients with sporadic IPF (176). Therefore, ER stress mediated-CHOP expression in 
alveolar epithelial type Ⅱcells plays an essential role in fibrosis by inducing apoptosis of 
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this cell type. Hypersecretion of prostaglandin E2 induces IL-8 generation in cystic fibrosis 
bronchial epithelial cells, which is positively regulated by CHOP at transcription level 
(177). Because IL-8 is a powerful chemoattractant for neutrophils that play a critical role in 
inflammatory reactions in cystic fibrosis, CHOP enhances development of cystic fibrosis 
by increasing IL-8 transcription and subsequent neutrophil accumulation (177).  Therefore, 
IPF is worsened by CHOP expression-mediated apoptosis of alveolar epithelial type Ⅱ
cells and neutrophil accumulation. 
However, CHOP expression can also have protective effects against acute lung 
injury. Both in vitro and in vivo studies show that CHOP expression is significantly 
increased by hyperoxia, which is dependent on double-stranded RNA-activated protein 
kinase pathway, but independent on p53 and ER stress-mediated signaling cascades (178, 
179). CHOP expression is restricted to the bronchiolar epithelial cells, which is 
demonstrated by in site hybridization and immunohistochemistry (179). When compared 
with wild type mice, CHOP knockout mice are more sensitive to hyperoxia-induced 
pulmonary injury, as evidenced by increased lung edema and permeability (178). 
Therefore, increased CHOP expression induced by hyperoxia protects mice from 
hyperoxia-mediated acute pulmonary injury by boosting DNA repair (178-180).    
Experimental Hypotheses 
C/EBPs α, β, δ, ε, , and ζ comprise a family of basic region-leucine zipper 
transcription factors that dimerize through a leucine zipper and bind to DNA through an 
adjacent basic region (181). Among them, C/EBPβ and C/EBPδ appear to be effectors in 
the induction of genes responsive to LPS, IL-1, or IL-6 stimulation, and have been 
implicated in the regulation of inflammatory mediators as well as other gene products 
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associated with the activation of macrophages and the acute-phase inflammatory response 
(126, 182-187). Both C/EBPβ and C/EBPδ are expressed in the lung, and agents including 
classical acute-phase stimuli as well as those causing acute lung injury such as bleomycin 
and oxidative stress have been shown to increase the levels of C/EBPβ and C/EBPδ in the 
lung (134, 188). However, the signals that mediate the activation of C/EBPβ and C/EBPδ 
and their functions in macrophages and lungs during inflammation remain largely 
unknown. A recent study demonstrates that C/EBPβ in the airway epithelium mediates 
inflammatory and innate immune responses in lung to cigarette smoke (189). C/EBPβ is 
also reported to play an essential role in bleomycin-induced pulmonary fibrosis (144). 
These observations suggest that C/EBPβ and/or C/EBPδ may play important roles during 
lung inflammation. However, no information exists about the role of C/EBPβ and C/EBPδ 
in acute lung injury  
The IgG immune complex model in the rodent lung has been employed to 
determine the molecular mechanisms of acute lung inflammatory injury (98, 190). In this 
model, intra-alveolar deposition of IgG immune complexes results in an acutely damaging 
process that affects capillary endothelial cells and alveolar epithelial cells, and also 
stimulates alveolar macrophages. Activation of alveolar macrophages results in formation 
of the early response cytokines such as TNF-α and IL-6, which induce expression of 
adhesion molecules on leukocytes and on endothelial cells/epithelial cells, all of which 
trigger a strong proinflammatory cascade. The induction of cytokine and chemokine gene 
expression involves the actions of specific transcription factors. For example, the 
activation of NF-κB and AP-1 has been observed in IgG immune complex-injured lung (61, 
63). However, their functions in IgG immune complex-induced lung injury are only 
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speculative, and no definitive study demonstrates their pivotal roles in the development of 
lung inflammatory responses. Our recent study indicates that STAT3 may play an 
important role in IgG immune complex-induced inflammation in macrophages and lungs 
(93), but the molecular mechanisms responsible for this observation remain to be defined. 
In this regard, C/EBPβ and C/EBPδ have been demonstrated to be targets of STAT3 (191, 
192).  
The central hypothesis is that the activities of C/EBPβ and C/EBPδ are induced in 
immune complex-induced inflammation, and they may play an important regulatory role in 
FcR-mdeiated inflammatory responses. 
Problems 
The FcRs are a family of cell surface molecules that bind the Fc portion of IgG 
immunoglobulins. Different cell types bear different sets of FcRs, and their specificities 
for various antibody classes thus determine which types of cells will be engaged in given 
responses. Four types of FcRs are identified in mice: FcRⅠ, FcRⅡB, FcRⅢ, and the 
newest member, FcRⅣ. FcRⅠ, FcRⅢ, and FcRⅣ are activating receptors, all of 
which associate with FcR common -chain, whereas FcRⅡB is an inhibitory member. 
The corresponding human FcRs are FcRⅠA, FcRⅡA, FcRⅢA (activating), and Fc
ⅡB (inhibitory) receptors. Human FcRⅠA and mouse FcRⅠ have high affinity for IgG. 
Based on the sequence similarity, human FcRⅡA is most closely related to mouse FcR
Ⅲ, and human FcRⅢA seems to be the orthologue of mouse FcRⅣ (6). However, 
human FcRⅡA has an immunoreceptor tyrosine-based activation motif in its cytosolic 
domain, which is not present in mouse FcRⅢ  and does not require -chain for 
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functionality (6). Macrophages, the sentinels of innate immunity, play key roles in 
inflammation. Activation of macrophages by FcRs triggers a wide variety of cellular 
responses (6, 193). In addition to phagocytosis, one of the major cellular responses in 
macrophages initiated by IgG immune complex (IC)-mediated FcR cross-linking is the 
activation of genes encoding chemokines and cytokines important in inflammation. 
Although the production of these mediators is mainly controlled at the transcriptional level 
in response to various inflammatory stimuli, the key nuclear molecules that mediate FcR 
signaling in macrophages remain unknown. Several transcription factors, such as NF-κB, 
AP-1, C/EBPβ, and STAT3, are activated in macrophages/monocytes following IgG IC 
stimulation (10, 194). Studies using pharmacological inhibitors suggest that NF-κB 
activation is involved in the expression of several chemokines, including MIP-1α and 
MIP-1β, upon cross-linking of FcR (194, 195). However, these lines of evidence are 
either indirect or correlative. Therefore, additional studies are necessary to elucidate the 
molecular mechanisms whereby the expression of inflammatory mediators is induced by 
FcRs. 
C/EBPα, β, δ, ε, , and ζ comprise a family of basic region-leucine zipper (bZIP) 
transcription factors that dimerize through a leucine zipper motif and bind to DNA through 
an adjacent basic region. C/EBPβ and -δ have been implicated in the regulation of 
inflammatory mediators as well as other gene products associated with the activation of 
macrophages and the acute phase inflammatory response (196). Two major forms of 
C/EBPβ are translated from the same messenger RNA, LAP and LIP (137). The roles of 
C/EBP family members in regulating inflammation have also been studied using knockout 
mice. Interestingly, the LPS stimulation of peritoneal macrophages from C/EBPβ deficient 
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mice leads to normal induction of several inflammatory cytokines, including IL-6 and 
TNF-α, with the exception of granulocyte colony-stimulating factor (G-CSF), Mincle, and 
microsomal prostaglandin E synthase-1 (mPGES-1) (143, 184, 197, 198), although 
macrophages from these mice demonstrate defective intracellular bacteria killing. 
Similarly, C/EBPδ deficient macrophages show nominal defects in IL-6 and TNF-α 
production in response to several TLR ligands (199). In contrast, the absence of both 
C/EBPβ and -δ results in a significant decrease in the TLR ligand-induced production of 
both IL-6 and TNF-α (199). In another study, Gorgoni et al. find that LPS-induced 
expression of IL-1β, TNF-α, IL-6, and inducible nitric-oxide synthase is partially impaired 
in C/EBPβ deficient macrophages and that expression of IL-12 p35 is completely defective 
(183). However, IL-12 p40, RANTES, and MIP-1β are more efficiently induced in 
response to IFN- and LPS in the absence of C/EBPβ (183). These results raise the 
possibility that the redundant expression of multiple C/EBP isoforms as well as differences 
in C/EBP homo-/heterodimer occupancy in specific gene promoters may account for the 
differential effects of C/EBPβ and -δ deficiency. Thus, the role of C/EBPβ and -δ in 
regulating transcription of the different inflammation-regulated mediators warrants further 
investigation. Furthermore, whether and how C/EBPβ and -δ are involved in the 
FcR-induced inflammatory response remains unclear, and the signals that mediate the 
activation of C/EBPβ and –δ are unknown. Furthermore, the roles of C/EBPβ and C/EBPδ 






Cells and Reagents 
RAW264.7 cells (ATCC; TIB-71TM) and MH-S cells (ATCC; CRL-2019™) were 
obtained from the American Type Culture Collection (Manassas, VA). RAW264.7 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 10% FBS, 2 mM L- glutamine, 100 U/ml penicillin, 100 mg/ml 
streptomycin, and maintained in a humidified incubator at 37°C with 5% CO2; MH-S cells 
were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 
100 U/ml penicillin, 100 mg/ml streptomycin, and 0.01 M HEPES, and maintained in a 
humidified incubator at 37°C with 5% CO2. ΨCREJ2 cells (a producer cell line for the J2 
retrovirus (200) kindly provided by H. Young) were maintained in DMEM supplemented 
with 10% heat inactivated fetal bovine serum (FBS; Hyclone, Rockford, IL), 200 mM 
L-glutamine, and 100 units/ml penicillin-streptomycin (Invitrogen). Transformed C/EBP 
deficient macrophage cell lines were generated from bone marrow of mice lacking C/EBPβ 
and/or C/EBPδ as well as their wild type littermates (201, 202). Bone marrow was 
collected from the femurs and tibias and placed into phosphate-buffered saline (PBS) 
containing 2% FBS. The bone marrow plugs were disaggregated and pelleted, and red 
blood cells were lysed using NH4Cl lysis solution (Sigma). The cells were cultured in 
DMEM supplemented with 10% heat-inactivated FBS, 100 ng/ml macrophage 
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colony-stimulating factor (Pepro- tech, Rocky Hill, NJ), 200 mM L-glutamine, 100 
units/ml penicillin-streptomycin. After 24 h, macrophages suspended in the medium were 
collected by centrifugation. To generate immortalized macrophage cell lines, 1–5 × 107 
BM cells were resuspended in ΨCREJ2 cell supernatant supplemented with 8 μg/ml 
Polybrene (Sigma) and 100 ng/ml macrophage colony-stimulating factor. ΨCREJ2 cell 
supernatant was removed after 24 h, and cell lines were maintained in DMEM 
supplemented with 10% heat-inactivated FBS, 100 ng/ml macrophage colony-stimulating 
factor, 200 mM L-glutamine, 100 units/ml penicillin-streptomycin. Rabbit anti-BSA IgG 
was purchased from ICN Biomedicals (Solon, OH). ELISA kits for mouse IL-6, TNF-α, 
MIP-2, KC, MIP-1α, MIP-1β, and soluble ICAM-1 (sICAM-1) were obtained from R&D 
Systems (Minneapolis, MN). p38 MAPK inhibitor Ⅷ and ERK1/2 inhibitor, U0126, were 
purchased from EMD Biosciences (Gibbstown, NJ). C5a and BSA were purchased from 
Sigma-Aldrich.  
Expression Vectors and Promoter Reporters 
The mouse IL-6 promoter-reporter (-250 to +1), TNF-α promoter-reporter 
containing sequences extending to -1260 bp, C/EBPβ expression vector as well as the 
C/EBPδ expression vector are kindly provided by Richard C. Schwartz (Michigan State 
University). The reporter plasmid (2 × C/EBP-Luc) containing two copies of a C/EBP 
binding site is kindly provided by Peter F. Johnson (NCI-Frederick). NF-κB 
promoter-reporter was obtained from Promega, Madison, WI.  
Luciferase Assay 
Transient transfections were performed with RAW264.7 or MH-S cells plated in 
12-well plates by using 0.5 μg of DNA and 1.5 μl of Fugene6 transfection reagent (Roche 
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Applied Science) in 50 μl of Opti-MEM I medium (Invitrogen). 24 h after transfection, the 
cells were treated either with or without 100 μg/ml IgG IC for the indicated time periods. 
Then cell lysates were subjected to luciferase activity analysis by using the 
Dual-Luciferase reporter assay system (Promega, Madison, WI). IgG IC were formed by 
the addition to anti-BSA of BSA at the point of antigen equivalence as described 
previously (203).  
siRNA Transfection 
Transient siRNA transfections were performed by transfecting 1-2 × 106 cells with 
600 nM control siRNA or C/EBPβ/δ siRNA (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) using the Amaxa® nucleofector kit V. 12 h later, the cells were treated with or without 
100 μg/ml IgG IC for the indicated time periods. Then supernatants were collected for 
ELISA analysis. 
Peritoneal Macrophage Isolation and Culture 
8–9-Weekold specific pathogen-free male C57BL/6 mice were obtained from 
Jackson Laboratories. FcR- and FcRⅡ-deficient mice were obtained from Taconic. 
C5aR knock-out mice were kindly provided by Craig Gerard (Harvard Medical School). 
C/EBPβ-/- and C/EBPδ-/- mice have been described previously (201, 202). Mouse 
peritoneal macrophages were isolated by using the thioglycollate method. Briefly, mice 
were injected intraperitoneally with 1.5 ml of 2.4% sterile thioglycollate dissolved in 
double distilled H2O. Peritoneal macrophages were obtained by instillation and aspiration 
of 10 ml of PBS 4 days after thioglycollate administration. The macrophages were 
maintained in DMEM supplemented with 5% FBS and allowed to adhere for 2 h, followed 
by 100 μg/ml IgG IC treatment for the indicated time periods. The supernatants were 
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harvested and subjected to ELISA analysis. The purity of the cell suspension was about 
99%, which was determined by staining of the peritoneal cell suspension with the HEMA 
3® Stain Set (Fisher). 
Alveolar Macrophage Isolation and in vitro IgG IC Treatment 
BAL fluids were collected using repetitive (three times) instillation and withdrawal 
of 1 ml saline via an intratracheal cannula. BAL samples were centrifuged at 1500 rpm for 
10 min, and cell pellets were resuspended and plated in 96-well plate. Alveolar 
macrophages (2-2.5 × 104/well) were allowed to adhere at 37°C for 1 h, and nonadhering 
cells were removed, followed by 100 μg/ml IgG IC treatment for the indicated time periods. 
The supernatants were harvested and subjected to ELISA analysis. The purity of the cell 
suspension was about 96%, which is determined by staining of BAL cells with HEMA 3® 
Stain Set. 
ELISA 
The cell supernatants or BAL fluids were centrifuged at 3000 rpm for 5 min, and 
the cell-free supernatants or BAL fluids were harvested for IL-6, TNF-α, MIP-2, KC, 
MIP-1α, MIP-1β, and soluble ICAM-1 (sICAM-1) measurements according to the 
manufacturer’s protocols. 
RNA Isolation and Analysis by Semiquantitative RT-PCR 
Total RNAs were extracted from cells with TRIzol (Invitrogen) according to the 
manufacturer’s procedure. After isolation, total cellular RNA was incubated with RQ1 
RNase-free DNase (Promega, Madison, WI) to remove contaminating DNA. 2 μg of total 
RNA was submitted to reverse transcription by using Superscript Ⅱ RNase H reverse 
transcriptase (Invitrogen). PCR was performed with the following primers: for C/EBPβ, 5’ 
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primer (5’-CAA GCT GAG CGA CGA GTA CA-3’) and 3’ primer (5’- AGC TGC TCC 
ACC TTC TTC TG-3’); for C/EBPδ, 5’ primer (5’-CGC AGA CAG TGG TGA GCT T-3’) 
and 3’ primer (5’-CTT CTG CTG CAT CTC CTG GT-3’); for TNF-α: 5’ primer, 5’- CGT 
CAG CCG ATT TGC TAT CT -3’ and 3’ primer, 5’- CGG ACT CCG CAA AGT CTA 
AG -3’; for MIP-1α: 5’ primer, 5’- ATG AAG GTC TCC ACC ACT GC -3’ and 3’ primer, 
5’- CCC AGG TCT CTT TGG AGT CA -3’; for MIP-2: 5’ primer, 5’- AGT GAA CTG 
CGC TGT CAA TG -3’ and 3’ primer, 5’- TTC AGG GTC AAG GCA AAC TT -3’for 
GAPDH, 5’ primer (5’-GCC TCG TCT CAT AGA CAA GAT G-3’) and 3’ primer 
(5’-CAG TAG ACT CCA CGA CAT AC-3’). After a “hot start” for 5 min at 94 °C, 28–33 
cycles were used for amplification with a melting temperature of 94 °C, an annealing 
temperature of 60 °C, and an extending temperature of 72 °C, each for 1 min, followed by 
a final extension at 72 °C for 8 min. PCR was performed using different cycle numbers for 
all primers, to ensure that DNA was detected within the linear part of the amplifying curves 
for both primers. 
RNA Isolation and Analysis by Real-time PCR 
Total RNAs were extracted from lungs with TRIzol, according to the 
manufacturer’s procedure. After isolation, total cellular RNA was incubated with RQ1 
RNase-free DNase to remove contaminating DNA. A quantity amounting to 2 μg total 
RNA was submitted to reverse transcription by using the Superscript Ⅱ RNase H-Reverse 
Transcriptase. Following reverse transcription, the cDNA (2 μl) was amplified and 
quantified using a Sequence Detection System (SDS 7300; Applied Biosystems, Foster 
City, CA) and a PCR universal protocol as follows: AmpliTaq Gold activation at 95°C for 
15 s and annealing/extension at 60°C for 1 min. The fluorescence of the double-stranded 
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products accumulated was monitored in real time. The levels of mRNA of TNF-α, IL-6, 
MIP-2, ICAM-1, VCAM-1, KC, MIP-1β, and MIP-1α were determined by quantitative 
real-time PCR. PCR was performed with primers for TNF-α, 5’ primer, 5’-CGT CAG 
CCG ATT TGC TAT CT-3’ and 3’ primer, 5’-CGG ACT CCG CAA AGT CTA AG-3’; 
KC, 5’ primer, 5’-GCT GGG ATT CAC CTC AAG AA-3’ and 3’ primer, 5’-TGG GGA 
CAC CTT TTA GCA TC-3’; IL-6, 5’ primer, 5’-AGT TGC CTT CTT GGG ACT GA-3’ 
and 3’ primer, 5’- TCC ACG ATT TCC CAG AGA AC-3’; MIP-2, 5’ primer, 5’-AGT 
GAA CTG CGC TGT CAA TG-3’ and 3’ primer, 5’-TTC AGG GTC AAG GCA AAC 
TT-3’; MIP-1α, 5’ primer, 5’-ATG AAG GTC TCC ACC ACT GC-3’ and 3’ primer, 
5’-CCC AGG TCT CTT TGG AGT CA-3’; MIP-1β, 5’ primer, 5’-GCC CTC TCT CTC 
CTC TTG CT-3’ and 3’ primer, 5’-GTC TGC CTC TTT TGG TCA GG-3’; ICAM-1, 5’ 
primer, 5’-TTC ACA CTG AAT GCC AGC TC-3’ and 3’ primer, 5’-GTC TGC TGA 
GAC CCC TCT TG-3’; VCAM-1, 5’ primer, 5’-ATT TTC TGG GGC AGG AAG TT-3’ 
and 3’ primer, 5’-ACG TCA GAA CAA CCG AAT CC-3’. The relative mRNA levels 
were normalized to levels of GAPDH mRNA in the same sample. 
Western Blot Analysis 
RAW264.7 cells were lysed in cold radioimmune precipitation assay buffer. 
Samples containing 80 μg of protein were electrophoresed in a 12% polyacrylamide gel 
and then transferred to a PVDF membrane. Membranes were incubated with rabbit 
anti-C/EBPβ antibody (Santa Cruz Biotechnology, Inc.), rabbit anti-C/EBPδ antibody 
(Santa Cruz Biotechnology, Inc.), rabbit anti-phospho-p38 MAPK antibody (Cell 
Signaling), rabbit anti-phospho-p44/42 MAPK antibody (Cell Signaling), rabbit anti-p38 
MAPK antibody (Cell Signaling), rabbit anti-p44/42 antibody (Cell Signaling), and rabbit 
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anti-GAPDH antibody (Cell Signaling), respectively. After three washes in TBST, the 
membranes were incubated with a 1:5000 dilution of horseradish peroxidase-conjugated 
donkey anti-rabbit IgG (GE Healthcare). The membrane was developed by the enhanced 
chemiluminescence technique according to the manufacturer’s protocol (Thermo Fisher 
Scientific, Rockford, IL). 
Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts of RAW264.7 cells, primary peritoneal macrophages, or MH-S 
cells were prepared as follows. Cells were lysed in 15 mM KCl, 10 mM HEPES (pH 7.6), 2 
mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1% (v/v) Nonidet P-40, 0.5 mM 
phenylmethylsulfonyl fluoride, and complete protease inhibitors (Roche, Indianapolis, IN) 
for 10 min on ice. Nuclei were pelleted by centrifugation at 14,000 × g for 20 sec at 4C. 
Proteins were extracted from nuclei by incubation at 4°C with vigorous vortexing in buffer 
C (420 mM NaCl, 20 mM HEPES (pH 7.9), 0.2 mM EDTA, 25% (v/v) glycerol, 1 mM 
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and complete protease inhibitors 
(Roche, Indianapolis, IN). Nuclear extracts of whole lung tissues were prepared as 
described previously (62). Briefly, frozen lungs were homogenized in 0.6% (v/v) Nonidet 
P-40, 150 mM NaCl, 10 mM HEPES (pH 7.9), 1 mM EDTA, 0.5 mM 
phenylmethylsulfonyl fluoride, 5 μg/ml antipain, 17 μg/ml calpain inhibitor, and 1×HaltTM 
Protease Inhibitor.  The homogenate was incubated on ice for 5 min and then centrifuged 
for 5 min at 5000 x g at 4°C.  Proteins were extracted from the pelleted nuclei by incubation 
at 4°C with solution B (420 mM NaCl, 20 mM HEPES (pH 7.9), 1.2 mM MgCl2, 0.2 mM 
EDTA, 25% (v/v) glycerol, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 
5 μg/ml antipain, 17 μg/ml calpain inhibitor, and 1×HaltTM Protease Inhibitor. Nuclear 
debris was pelleted by centrifugation at 5000 × g for 5 min at 4°C, and the supernatant 
extract was collected and stored at 80°C. Protein concentrations were determined by 
Bio-Rad protein assay kit (Thermo Fisher Scientific, Rockford, IL). The EMSA probes 
were C/EBP consensus oligonucleotide (TGCAGATTGCGCAATCTGCA, Santa Cruz 
Biotechnology, Inc.), or a NF-B consensus oligonucleotide 
(AGTTGAGGGGACTTTCCCAGGC, Promega, Madison, WI).  C/EBP probes and 
NF-B probes were labeled with γ [32P] ATP (3,000 Ci/mmol at 10 mCi/ml, GE Healthcare, 
Piscataway, NJ). DNA binding reactions were performed at room temperature in a 25 l 
reaction mixture containing 6 l of nuclear extract (1 mg/ml in buffer C or solution B) and 
5 l of 5 × binding buffer (20% (w/v) Ficoll, 50 mM HEPES pH 7.9, 5 mM EDTA, 5 mM 
dithiothreitol). The remainder of the reaction mixture contained KCl at a final 
concentration of 50 mM, Nonidet P-40 at a final concentration of 0.1%, 1 g of poly 
(dI-dC), 200 pg of probe, bromphenol blue at a final concentration of 0.06% (w/v), and 
water to final volume of 25 μl.  Samples were electrophoresed through 5.5% 
polyacrylamide gels in 1 × TBE at 190 V for approximately 3.5 h, dried under vacuum, and 
exposed to X-ray film. For supershifts, nuclear extracts were preincubated with antibodies 
(1 to 2 g) for 0.5 h at 4°C prior to the binding reaction.  The following antibodies were 
purchased from Santa Cruz, CA: C/EBPα, C/EBPβ, C/EBPδ, C/EBPε, C/EBPγ, and 
normal rabbit immunoglobulin G.  
IgG IC-induced Acute Lung Injury 
 46
All procedures involving mice were approved by the Animal Care and Use 
Committee of Harvard Medical School. Eight- to 12-wk-old specific pathogen-free male 
C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Generation 
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of C/EBPβ- and C/EBPδ-deficient mice by homologous recombination has been described 
previously (201, 202). C/EBPβ knockout mice and wild type littermates are on a 
C57BL/6:Sv129 F1 hybrid background (to circumvent low mutant viability on each pure 
strain background), and C/EBPδ knockout animals and wild type controls are on a 
C57BL/6 background. IgG immune complexes-mediated acute lung injury was induced as 
described previously (18, 62, 93, 98). Briefly, mice were anesthetized intraperitoneally 
(i.p.) with ketamine HCl (100 mg/kg), followed by intratracheal instillation of 40 μl rabbit 
anti-BSA IgG dissolved in PBS (6 mg/ml) during inspiration. Immediately after 
intratracheal injection of anti-BSA, mice received intravenous (i.v.) 200 μl BSA solution 
(5 mg/ml in PBS). Negative control mice received anti-BSA IgG or PBS intratracheally 
alone. Unless otherwise indicated, 4 h after IgG immune complex deposition, mice were 
exsanguinated and the pulmonary circulation was flushed with 1 ml PBS via the pulmonary 
artery. The lungs were surgically dissected and immediately frozen in liquid nitrogen. 
Myeloperoxidase Activity 
Mice were sacrificed, and the lungs were perfused via the right ventricle with 3 ml 
PBS. Myeloperoxidase (MPO) is a peroxidase enzyme, which is abundantly generated in 
neutrophils, and its activity is the marker of neutrophil content. To measure MPO activity, 
whole lungs were homogenized in 50 mmol/l potassium phosphate buffer containing 0.5% 
hexadecyltrimethylammonium bromide and 5 mmol/L EDTA. The samples were sonicated 
for 1 min and centrifuged at 10,000 rpm for 10 min. A total of 10 μl recovered supernatants 
was added to 96-well plates, followed by addition of 100 mmol/l potassium phosphate 
buffer containing 1.5 mol/l H2O2 and 167 μg/ml o-dianisidine dihydrochloride. The 
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enzyme activity was determined by measuring the change in OD at 450 nm over a period of 
4.5 min using a 96-well plate reader. 
Histological Assay 
Four hours after IgG immune complex deposition, 1 ml 10% buffered (PH 7.2) 
formalin was instilled into the lung via the trachea. The lungs were then surgically removed 
and further fixed in 10% buffered formalin solution for morphological assay by tissue 
sectioning and staining with H&E. 
Cell Count and Albumin Concentration Assay in BAL Fluids 
Four hours after initiation of the acute lung injury, the thorax was opened and 0.8 
ml ice-cold, sterile PBS was instilled into the lung via a tracheal incision. The recovered 
BAL fluid was centrifuged at 3000 rpm for 5 min, and the cell-free supernatants were 
stored at -20°C. Cell pellets were resuspended in 1 ml HBSS containing 0.5% BSA, and 
differential cell analyses were performed by Diff-Quik–stained cytospin preparations 
(Dade, Duedingen, Switzerland) counting a total of 300 cells per slide in randomly selected 
high-powered fields (× 1000). Mouse albumin levels in BAL fluid were measured using a 
mouse albumin ELISA kit purchased from Bethyl Laboratories (Montgomery, TX). The 
permeability index was expressed as the ratio of the albumin in the IgG immune 
complex-injured lungs versus that in the control-treated lungs of same type of mice. 
Alveolar Macrophage Depletion 
Mice were anesthetized with ketamine HCl (100 mg/kg, i.p.). A suspension of 
dichloromethylene diphosphonate (Cl2MDP) liposomes in PBS (10 μl of the liposome 
stock in a total volume of 50 μl) was administered intratracheally during inspiration. As a 
control, PBS liposomes were administered in a similar fashion. All subsequent 
 49
interventions were performed 24 h after liposome instillation. Liposome-encapsulated 
clodronate was prepared, as previously described (204). Mice receiving Cl2MDP 
liposomes showed more than 75% depletion of alveolar macrophages compared with mice 
receiving PBS liposomes. Administration of PBS liposomes did not reduce the number of 
alveolar macrophages. 
Statistical Analysis 
All values were expressed as the mean  S. E..  Significance was assigned where p 
< 0.05.  Data sets were analyzed using Student’s t test or one-way ANOVA, with 





Roles of C/EBPβ and –δ in IgG IC-induced Inflammation in Macrophages 
IgG IC Induces Expression of C/EBPβ and -δ in Macrophages 
To determine if C/EBP activities were induced by IgG IC, I first examined the 
DNA binding activity of C/EBPs in RAW264.7 macrophages, which is the most popular 
peritoneal macrophage-derived cell line. As shown in Fig. 1A, RAW264.7 cells were 
challenged with IgG IC for different time periods, and extracted nuclear proteins were 
subjected to EMSA. The results showed that strong C/EBP DNA binding activity was 
induced after IgG IC stimulation (Fig. 1A). To determine which C/EBP family members 
were induced by IgG IC, supershift assays were performed. There are five major 
DNA-binding species in the nuclear proteins of control-treated macrophages, as follows: 
C/EBP LAP/C/EBP heterodimers, C/EBP LIP/C/EBP heterodimers, heterodimers 
LAP and LIP, LAP/LAP homodimers, and LIP/LIP homodimers (Fig. 1B). In IgG immune 
complex-treated macrophages, the DNA-binding activities of both C/EBPβ (mainly 
LAP/LIP, LAP/LAP and LIP/LIP) and C/EBPδ were markedly induced (Fig. 1B). I further 
examined the IgG IC-induced C/EBP activation in transient transfections using 2 × 
C/EBP-Luc, a promoter-reporter that contains two copies of a canonical C/EBP binding 
site, and expression vectors for C/EBPβ and/or C/EBPδ. These transfections were carried 















Figure 1. IgG Immune Complex Treatment Increases C/EBPβ and -δ DNA Binding 
Activities. A, RAW264.7 cells were stimulated with 100 μg/ml IgG IC for the times 
indicated. Nuclear proteins were harvested and subjected toEMSA to measure C/EBP 
DNA binding activity. B, RAW264.7 cells were treated or left untreated with 100 μg/ml 
IgG immune complexes for 4 h. The nuclear extracts were harvested for gel supershift 
assay to identify which C/EBP family member DNA binding activity was regulated by IgG 
immune complex treatment. N, α, β, δ, ε, and  indicate normal rabbit IgG, anti-C/EBPα 
antibody, anti-C/EBPβ antibody, anti-C/EBPδ antibody, anti-C/EBPε antibody, and 
anti-C/EBP antibody, respectively. The arrows indicate C/EBP complex and supershift 

































Figure 2. IgG Immune Complex Stimulation Augments C/EBP Transcriptional Activity. 
RAW264.7 cells were transiently transfected with a total of 0.5 μg of the indicated DNA. 
24 h after transfection, the cells were treated with 100 μg/ml IgG immune complex for 5 h. 
Cell lysates were used to perform a luciferase activity assay. Luminometer values were 
normalized for expression from a co-transfected thymidine kinase reporter gene. The data 




stimulation alone increased luciferase activity 4-fold compared with the control group (Fig. 
2). IgG IC treatment of C/EBPβ, C/EBPδ, and C/EBPβ plus C/EBP transfectants induced 
luciferase expression 14-, 10-, and 19-fold, respectively, over the control value. 
Interestingly, overexpression of C/EBPβ, C/EBPδ, and C/EBPβ plus C/EBPδ alone 
stimulated luciferase activity 4-, 2.6-, and 6.2-fold, respectively; this is less than the values 
observed in the presence of IgG IC. These data suggest that IgG IC signaling may stimulate 
C/EBP transcriptional activity in addition to inducing expression of the endogenous 
proteins. Moreover, C/EBPβ and -δ together were more potent activators than either 
protein alone, indicating that C/EBPβ and -δ are preferential dimerization partners, 
C/EBPβ/δ heterodimers have stronger DNA binding activity than homodimers, or both. 
I next examined whether IgG IC induced expression of C/EBPβ and -δ at the 
mRNA level. RT-PCR showed that C/EBPβ and -δ mRNAs were highly induced in 
RAW264.7 cells following a 24-h treatment with IgG IC (Fig. 3A). I then sought to 
determine whether this induction resulted in increased abundance of C/EBPβ and -δ 
proteins in RAW264.7 cells. The Western blot analysis of proteins isolated over a time 
course of IgG IC treatment revealed a time-dependent increase in the abundance of both 
C/EBPβ (mainly LAP) and C/EBPδ proteins (Fig. 3B). These data demonstrate that 
increased abundance of C/EBPβ and -δ is coincident with their increased DNA binding 
activity in RAW264.7 cells. 
C/EBPβ and -δ are Required for IgG IC-mediated Cytokine and Chemokine Expression in 
Macrophages 
 C/EBPβ and -δ play important roles in regulating inflammatory responses in many 
different cells, including macrophages (182, 183, 199, 205-207). However, whether they
 
Figure 3. IgG Immune Complexes Induce C/EBPβ and -δ Expressions. A, RAW264.7 cells 
were stimulated with 100 μg/ml IgG immune complexes for different time periods. Then 
total cellular RNA was isolated for RT-PCR with primers for C/EBPβ, C/EBPδ, and 
GAPDH, respectively. B, RAW264.7 cells were stimulated with 100 μg/ml IgG immune 
complexes for different time periods. Then total cellular proteins were extracted to conduct 
Western blot using rabbit anti-C/EBPβ antibody, rabbit anti-C/EBPδ antibody, and rabbit 
anti-GAPDH antibody, respectively. The level of GAPDH is shown at the bottom as a 
loading control. The same experiment was repeated once. 
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are involved in macrophage inflammatory responses after FcR cross-linking is unknown. 
TNF-α is an early proinflammatory cytokine secreted by macrophages during 
inflammation. Both MIP-2 and MIP-1α were initially identified as monokines secreted 
from LPS stimulated RAW264.7 cells (208-211). MIP-2 belongs to the C-X-C chemokine 
subfamily and has been shown to possess potent chemotactic activity for neutrophils, 
whereas MIP-1α, as a member of the C-C chemokine subfamily, has been shown to 
chemoattract leukocytes of the monocyte lineage (208, 209, 212, 213). Therefore, I sought 
to determine the effect of C/EBPβ and -δ deficiency on the expression of TNF-α, MIP-2, 
and MIP-1α from IgG-IC-stimulated macrophages. To that end, I first showed that both 
C/EBPβ and -δ expression were efficiently depleted by their respective siRNAs in 
RAW264.7 cells (Figs. 4A and 6A). IgG immune complexes dramatically increased 
expressions of TNF-α, MIP-2, and MIP-1α at transcriptional level in control cells, whereas 
all were markedly reduced when C/EBPβ or -δ was ablated, and the numbers indicated 
relative abundance of gene expression (Figs. 4B and 6B). To examine if knockdown of 
C/EBPβ or -δ could lead to a corresponding reduction in secretion of these 
proinflammatory proteins, I performed ELISA analysis. As shown in Figs. 5 and 7, the 
secretions of TNF-α, MIP-2, and MIP-1α from RAW264.7 cells were all markedly 
stimulated by IgG immune complexes treatment. However, when compared with control 
siRNA treatment, C/EBPβ siRNA suppressed TNF-α production by ~60%, MIP-2 by 
~46%, and MIP-1α by ~25%, respectively. Furthermore, C/EBPδ knockdown inhibited 
TNF-α generation by ~43%, MIP-2 by ~17%, and MIP-1α by ~43%, respectively, as 















Figure 4. IgG IC-mediated Generation of Proinflammatory Mediators is Regulated by 
C/EBPβ at Transcription Level. A, RAW264.7 cells were transiently transfected with 
control siRNA, or C/EBPβ siRNA. 12 h later, RNAs were extracted and subjected to 
RT-PCR to examine expression of C/EBPβ, and GAPDH, respectively. B, RAW264.7 
cells were transiently transfected with control siRNA or C/EBPβ siRNA. 12 h later, cells 
were incubated with or without 100 μg/ml IgG IC for 4 h. Total RNA was extracted, and 
semi-quantitative RT-PCR was performed to examine expression of TNF-α, MIP-2, and 
MIP-1α, respectively. The level of GAPDH is shown at the bottom as a loading control. 


















Figure 5. IgG IC-mediated TNF-α, MIP-2, and MIP-1α Production is Regulated by 
C/EBP at Protein Level. RAW264.7 cells were transiently transfected with control 
siRNA or C/EBPβ siRNA. 12 h later, cells were incubated with or without 100 μg/ml IgG 
IC for 5 h. The supernatants were harvested, and ELISA was performed to determine the 
production of TNF-α (A), MIP-2 (B), and MIP-1 (C). Data are presented as mean ± S.E. 














Figure 6. IgG IC-mediated Generation of Proinflammatory Mediators is Regulated by 
C/EBP at Transcription Level. A, RAW264.7 cells were transiently transfected with 
control siRNA, or C/EBP siRNA. 12 h later, RNAs were extracted and subjected to 
RT-PCR to examine expression of C/EBP, and GAPDH, respectively. B, RAW264.7 
cells were transiently transfected with control siRNA or C/EBP siRNA. 12 h later, cells 
were incubated with or without 100 μg/ml IgG IC for 4 h. Total RNA was extracted, and 
semi-quantitative RT-PCR was performed to examine expression of TNF-α, MIP-2, and 
MIP-1α, respectively. The level of GAPDH is shown at the bottom as a loading control. 


















Figure 7. IgG IC-mediated TNF-α, MIP-2, and MIP-1α Production is Regulated by 
C/EBP at Protein Level. RAW264.7 cells were transiently transfected with control siRNA 
or C/EBP siRNA. 12 h later, cells were incubated with or without 100 μg/ml IgG IC for 5 
h. The supernatants were harvested, and ELISA was performed to determine the 
production of TNF-α (A), MIP-2 (B), and MIP-1 (C). Data are presented as mean ± S.E. 
(n=7–12). The same experiment was repeated twice. 
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I further determined whether the observed regulatory role of C/EBPβ and -δ on the 
IgG IC-induced TNF-α, MIP-2, and MIP-1α production in RAW264.7 cells was also 
applicable to primary macrophages. I first performed gel supershift assay in control, and 
IgG IC-treated peritoneal macrophages, respectively. There are six major DNA-binding 
species in the nuclear proteins of control-treated macrophages, as follows: C/EBP 
LAP/C/EBP heterodimers, C/EBP LIP/C/EBP heterodimers, LIP/C/EBP 
heterodimers, heterodimers LAP and LIP, LAP/LAP homodimers, and LIP/LIP 
homodimers (Fig. 8). The DNA binding activities of both C/EBPβ and -δ (to a minor extent) 
were induced by IgG IC (Fig. 8). I next demonstrated that, upon IgG IC treatment, 
C/EBPβ- or C/EBPδ-deficient macrophages released less amounts of TNF-α, MIP-2, and 
MIP-1α at all time points when compared with wild type macrophages (Fig. 9), consistent 
with the results obtained from RAW264.7 cells. In addition, I compared the IgG IC 
responses of four different immortalized macrophage cell lines established from WT, 
C/EBPβ-/-, C/EBPδ-/-, and C/EBPβ-/-/δ-/- cells. When compared with WT macrophages, 
C/EBPβ knockout suppressed TNF-α induction by ~80%, MIP-1α by ~58%, and MIP-2 by 
~77.7%, and C/EBPδ knockout also significantly inhibited production of TNF-α (~24%), 
MIP-1α (~49%), and MIP-2 (~34%) (Fig. 10). Moreover, C/EBPβ/δ double knockout 
further reduced secretion of TNF-α (~98%), MIP-1α (~99%), and MIP-2 (~98%) (Fig. 10). 
Thus, there is a redundant role for C/EBPβ and -δ in IgG IC-induced TNF-α, MIP-1α, and 
MIP-2 production in macrophages. Taken together, these findings show that C/EBPβ and 




Figure 8. IgG Immune Complex Treatment Elevates C/EBPβ and -δ DNA Binding 
Activity in Primary Peritoneal Macrophages. Primary peritoneal macrophages were 
obtained from wild type mice, and treated or left untreated with 100 μg/ml IgG immune 
complexes for 4 h. The nuclear extracts were harvested for gel supershift assay to identify 
which C/EBP family member DNA binding activity was regulated by IgG immune 
complex treatment. N, α, β, δ, ε, and , normal rabbit IgG, anti-C/EBPα antibody, 
anti-C/EBPβ antibody, anti-C/EBPδ antibody, anti-C/EBPε antibody, and anti-C/EBP 
antibody, respectively. The arrows indicate C/EBP complex and supershift species. The 

















Figure 9. IgG IC-mediated Inflammation is Decreased in Macrophages Lacking C/EBPβ or 
C/EBPδ. Primary peritoneal macrophages obtained from corresponding wild type, and 
C/EBPβ or C/EBPδ knockout mice were treated with 100 μg/ml IgG immune complex for 
different time periods, and supernatants were subjected to ELISA analysis for TNF-α (A, 
D), MIP-2 (B, E), and MIP-1 (C, F) production. Data are presented as mean ± S.E. (n=6). 


















Figure 10. C/EBPβ and -δ are Critical Regulators of Inflammatory Reactions in IgG 
IC-stimulated Macrophages. Macrophages obtained from corresponding wild type, 
C/EBPβ knockout, C/EBPδ knockout, and C/EBPβ/δ double knockout mice were treated 
with 100 μg/ml IgG immune complex for 5 h, and supernatants were subjected to ELISA 
analysis for TNF-α (A), MIP-2 (B), and MIP-1 (C) production. Data are presented as 
mean ± S.E., n=7-8. The same experiment was repeated once. 
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NF-κB plays a central role in coordinating immune and inflammatory responses. 
To test its involvement in IgG immune complex-induced inflammation, RAW264.7 cells 
were treated with a NF-κB inhibitor, BAY 11-7082 (Fig. 11). The data showed that upon 
IgG immune complex stimulation, the levels of all three mediators were down-regulated by 
BAY 11-7082, with a significant inhibitory effect on TNF-α and MIP-1α production, 
suggesting that NF-κB also plays an important regulatory role in IgG IC-induced cytokine 
and chemokine production. 
FcRs Trigger C/EBP-mediated Cytokine and Chemokine Production in IC-stimulated 
Macrophages 
 
FcRs exert both activating and inhibitory effects on inflammatory responses, and 
the cellular threshold for inflammation is dependent on the ratio of the opposing signaling 
FcRs. Because both activating and inhibitory FcRs (Fc receptors) are expressed on 
macrophages (6, 214), I sought to determine the role of FcRs in IgG immune 
complex-induced inflammatory reactions in macrophages. All the activating FcRs that 
have been identified share a common -chain usually expressed as FcR, which is required 
for inflammatory signaling transduction. Thus, FcR -chain deficiency can lead to 
disability of the activating FcRs. Using peritoneal macrophages from FcR -chain 
knockout mice, I first examined the influence of conventional activating FcRs on IgG 
immune complex-induced cytokine and chemokine production. As shown in Fig. 12A-C, 
FcR -chain mutation resulted in a significantly decreased production of TNF-α (~57%), 
MIP-2 (~38%), and MIP-1α (~45%) in IgG immune complex-treated macrophages 
compared with their wild type counterparts. In contrast, FcRⅡ deficiency resulted in an 

















Figure 11. NF-κB Plays an Important Role in IgG Immune Complex-induced 
Inflammatory Mediators’s Expressions. RAW264.7 cells were treated with 100 μg/ml IgG 
immune complex, or IgG immune complex plus NF-κB inhibitor BAY 11-7082 (2 μM) for 
5 h. Supernatants were harvested and subjected to ELISA analysis for generation of TNF-α 
(A), MIP-2 (B), and MIP-1 (C). Data are presented as ± S.E., n=6. The same experiment 
















Figure 12. Effect of FcR -chain Deficiency on IgG IC-induced Inflammation. Primary 
peritoneal macrophages obtained from wild type and FcR -chain knockout mouse were 
treated with 100 μg/ml IgG immune complex for 5 h, and supernatants were subjected to 
ELISA analysis for production of TNF-α (A), MIP-2 (B), and MIP-1 (C). Data are 
presented as ± S.E., n=8. D, Primary peritoneal macrophages obtained from corresponding 
wild type and FcR -chain deficient mice were treated or left untreated with 100 μg/ml IgG 
immune complexes for 4 h. The nuclear proteins were harvested and subjected to EMSA to 

















Figure 13. Effect of FcRⅡ  Deficiency on IgG IC-induced Inflammation. Primary 
peritoneal macrophages obtained from wild type and FcRⅡ knockout mouse were treated 
with 100 μg/ml IgG immune complex for 5 h, and supernatants were subjected to ELISA 
analysis for production of TNF-α (A), MIP-2 (B), and MIP-1 (C). Data are presented as ± 
S.E., n=8. D, Primary peritoneal macrophages obtained from corresponding wild type and 
FcRⅡ deficient mice were treated or left untreated with 100 μg/ml IgG immune 
complexes for 4 h. The nuclear proteins were harvested and subjected to EMSA to measure 
C/EBP DNA binding activity. The same experiment was repeated once. 
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Because the current data suggest that C/EBPβ and -δ may play important roles in cytokine 
and chemokine expression in IgG immune complex-stimulated macrophages, I next 
examined the effect of FcRs deficiency on C/EBPβ and -δ activation. I found that 
knockout of FcR -chain suppressed induction of C/EBP DNA binding activity (Fig. 12D). 
Furthermore, inhibitory FcRⅡ deficiency elevated C/EBP DNA binding activity (Fig. 
13D). In summary, these findings suggest that activating FcRs play an important role in 
IgG immune complex-induced C/EBPβ and -δ induction, leading to production of TNF-α, 
MIP-2, and MIP-1α, whereas the inhibitory FcR has an opposite effect. 
ERK1/2 and p38 MAPK are Involved in IgG IC-induced C/EBPβ and -δ Activation and 
Subsequent Cytokine/Chemokine Production 
 
Previous studies have shown that FcR cross-linking on macrophages/monocytes 
activates the extracellular signal-regulated kinases (ERK1/2, p44/42) and p38 MAPK 
signaling pathways (215, 216). However, whether ERK and p38 signaling pathways 
function as transducers connecting FcR stimulation to C/EBPβ and -δ activation remains 
unclear. To investigate this possibility, I first evaluated the MAPK pathways in IgG 
IC-stimulated macrophages. As shown in Figs. 14A and 16A, IgG IC treatment led to the 
phosphorylation of both ERK1/2 and p38 MAPK in a time-dependent manner. I next 
evaluated the influence of these phosphorylated MAPK on C/EBPβ and –δ activation by 
using specific pharmacological inhibitors for ERK1/2 and p38 MAPK. I observed that 
phosphorylation of ERK1/2 was greatly suppressed by U0126 at all time points (Fig. 14A). 
Though p38 MAPK activation was only markedly inhibited by p38 MAPK inhibitor Ⅷ at 
4-h time point, it had no influence on my subsequent experiments—EMSA and ELISA 















Figure 14. ERK1/2 is Involved in IgG IC-induced C/EBPβ and -δ Activation. A, 
RAW264.7 cells were treated with 100 μg/ml IgG immune complexes in the presence or 
absence of ERK1/2 inhibitor, U0126 (10 μM) for the indicated time periods. Total proteins 
were subjected to Western blot by using rabbit anti-phospho-p44/42 (p-p44/42) antibody 
and rabbit anti-p44/42 antibody, respectively. RAW264.7 cells were treated with 100 
μg/ml IgG IC in the presence or absence of U0126 for 4 h. The nuclear proteins were 
subjected to EMSA for C/EBP DNA binding (B), and NF-B DNA binding (C), 
respectively. The same experiment was repeated once. 
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presence of the inhibitor (Figs. 16 and 17). Further, U0126 and p38 MAPK inhibitor Ⅷ 
suppressed C/EBP DNA binding activity induced by IgG IC (Figs. 14B and 16B). The 
effect of MAPK inhibitors on IgG IC-induced NF-κB activation was also examined. 
EMSA showed that none of these inhibitors reduced NF-κB DNA binding activity (Figs. 
14C and 16C). Interestingly, U0126 slightly elevated IgG IC-induced NF-κB activation 
(Fig. 14C). To determine whether MAPK activation is involved in IgG IC-induced 
cytokine and chemokine production (which are regulated by C/EBPβ and -δ), I evaluated 
the effect of U0126 and p38 MAPK inhibitor Ⅷ on TNF-α, MIP-2, and MIP-1α secretion 
from RAW264.7 macrophages. As shown in Figs. 15 and 17, U0126 and p38 MAPK 
inhibitor VIII inhibited IgG IC-stimulated TNF-α, MIP-2, and MIP-1α production. To 
determine whether ERK1/2 and p38 MAPK acted in concert or sequentially downstream of 
FcRs, RAW264.7 cells were treated with both ERK1/2 inhibitor and p38 inhibitor. As 
shown in Fig. 18, when compared with p38 MAPK inhibitor Ⅷ or U0126 treatment alone, 
co-treatment resulted in a decreased production of TNF-α (~100%), MIP-2 (~100%), and 
MIP-1α (~66%). These data suggest that ERK1/2 and p38 MAPK act in concert to mediate 
IgG IC-induced inflammatory responses. 
C5a Enhances IgG IC-stimulated Cytokine and Chemokine Production by Elevating 
C/EBPs but Not NF-κB DNA Binding Activity 
 
C5a has been shown to synergistically enhance IgG immune complex-induced 
TNF-α and MIP-2 production in alveolar macrophages (30, 217). Thus, I examined the role 
of C5a in the activation of peritoneal macrophages treated with IgG immune complex. As 
shown in Fig. 19, the addition of C5a significantly increased IgG immune 


















Figure 15. p44/42 MAPK is Involved in IgG IC-induced Inflammation. RAW264.7 cells 
were treated with 100 μg/ml IgG immune complexes in the presence or absence of ERK1/2 
inhibitor, U0126 (10 μM) for 5 h, and supernatants were subjected to ELISA analysis for 
production of TNF-α (A), MIP-2 (B), and MIP-1 (C). Data are presented as mean ± S.E., 
















Figure 16. p38 MAPK is Involved in IgG IC-induced C/EBPβ and -δ Activation. A, 
RAW264.7 cells were treated with 100 μg/ml IgG immune complexes in the presence or 
absence of p38 MAP Kinases Inhibitor Ⅷ (10 μM) for the indicated time periods. Total 
proteins were subjected to Western blot by using rabbit anti-phospho-p38 (p-p38) antibody 
and rabbit anti-p38 antibody, respectively. RAW264.7 cells were treated with 100 μg/ml 
IgG IC in the presence or absence of p38 MAP Kinases Inhibitor Ⅷ for 4 h. The nuclear 
proteins were subjected to EMSA for C/EBP DNA binding (B), and NF-B DNA binding 



















Figure 17. p38 MAPK is Involved in IgG IC-induced Inflammation. RAW264.7 cells were 
treated with 100 μg/ml IgG immune complexes in the presence or absence of p38 MAPK 
inhibitor, p38 MAP Kinases Inhibitor Ⅷ (10 μM) for 5 h, and supernatants were subjected 
to ELISA analysis for production of TNF-α (A), MIP-2 (B), and MIP-1 (C). Data are 

















Figure 18. Both p38 and p44/42 MAPKs are Involved in IgG IC-induced Inflammation. 
RAW264.7 cells were treated with 100 μg/ml IgG immune complex in the presence or 
absence of both p38 MAP kinase Inhibitor Ⅷ(10 μM) and p44/42 inhibitor U0126 (10 μM) 
for 5 h. Supernatants were harvested and subjected to ELISA analysis for TNF- (A), 
MIP-2 (B), and MIP-1 (C). Data are presented as mean ± S.E., (n =6). The same 


















Figure 19. C5a Signaling Enhances IgG Immune Complex-induced Inflammation. Mouse 
peritoneal macrophages were treated with 10 nM recombinant human C5a, 100 μg/ml IgG 
immune complexes, or a combination of both stimuli for different time points, and 
supernatants were subjected to ELISA analysis for production of TNF- (A), MIP-2 (B), 




alone had no effect on these inflammatory mediators’ production. C5a plays a critical role 
in regulating the FcRⅢ/Ⅱ pair to connect complement and FcR pathways during 
immune complex-associated inflammatory responses (30). Furthermore, C5a can be 
generated by IC-stimulated macrophages (218). Therefore, I determined if C5a signaling 
plays a role in activation of C/EBPs and NF-κB, which may lead to the increased 
production of TNF-α, MIP-2, and MIP-1α. Reporter assays demonstrated that IgG immune 
complex-induced C/EBP activity, but not NF-κB activity, was further increased by the 
addition of C5a (Fig. 20A and B). Moreover, IgG immune complex-stimulated C/EBP 
DNA binding was significantly reduced in peritoneal macrophages from C5aR-deficient 
mice compared with wild type controls (Fig. 20C). In contrast, C5aR deficiency had no 
effect on NF-κB DNA-binding activity (Fig. 20D), consistent with the reporter data. Thus, 
C5a appears to have a specific role in activating C/EBPs. 
To further address the underlying mechanisms whereby C5a enhances IC-induced 
cytokine and chemokine production, I explored the influence of C5a on MAPK pathways. 
As shown in Fig. 21, C5a treatment further increased both phospho-p38 and 
phospho-p44/42 levels induced by IC in RAW264.7 cells. Thus, these data indicate that 
C5a enhances IC-induced cytokine and chemokine production by elevating phospho-p38 
and phospho-p44/42 levels, which lead to increased C/EBPβ and -δ activities. 
Roles of C/EBPβ and –δ in IgG IC-induced ALI 
Lung C/EBPs are Activated during IgG IC-induced Alveolitis 
Previous data have demonstrated the critical roles of C/EBPβ and –δ in IgG 
immune complex-induced inflammation in vitro, I then sought to examine their effects on 













Figure 20. C5a Signaling Enhances IgG IC-induced C/EBP Activation. A and B, 
RAW264.7 cells were transiently transfected with a total of 0.5 μg of DNA. 24 h after 
transfection, the cells were treated with 10 nM recombinant human C5a, 100 μg/ml IgG 
immune complexes, or a combination of both stimuli for 4 h. Cell lysates were used to 
perform the luciferase activity assay. Luminometer values were normalized for expression 
from a co-transfected thymidine kinase reporter gene. Data are presented as mean ± S.E., 
(n =3). The same experiment was repeated three times. Peritoneal macrophages obtained 
from wild type and C5aR deficient mice were treated with or without 100 μg/ml IgG IC for 
4 h, and nuclear proteins were subjected to EMSA for C/EBP (C), and NF-κB (D), 


















Figure 21. C5a Enhances IgG IC-induced p44/42 and p38 MAPKs Activation. RAW264.7 
cells were treated with 100 μg/ml IgG immune complex or IgG immune complex plus 10 
nM rhC5a for 4 h. Total proteins were extracted and subjected to Western blot by using 
rabbit anti-phospho-p44/42 (p-p44/42) antibody (A), rabbit anti-p44/42 antibody (A), 
rabbit anti-phospho-p38 (p-p38) antibody (B), rabbit anti-p38 antibody (B), and rabbit 
anti-GAPDH, repectively. The same experiment was repeated once. 
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injured lung by EMSA (Fig. 22A). C/EBP-binding species were detected in control-treated 
lung. Increased C/EBP binding was evident by 1 h after IgG immune complex deposition, 
and became strongest at 4 and 8 h. Subsequently, C/EBP-binding activity subsided, 
reaching basal levels by 24 h. To determine which C/EBP family members are induced by 
IgG immune complexes, I performed supershift assays. As shown in Fig. 22B, there are 
three major DNA-binding species in the nuclear proteins of control-treated lungs, as 
follows: low levels of C/EBPα/β heterodimers; heterodimers between C/EBPβ LAP and its 
short isoform, LIP, which is translated from an alternative start site in the same mRNA 
(137); and LIP/LIP homodimers. In IgG immune complex-injured lungs, the DNA-binding 
activities of both C/EBPβ (mainly β/LIP and LIP/LIP) and C/EBPδ were significantly 
induced (Fig. 22B). Using real-time RT-PCR analysis, I further show there is a 
time-dependent increase in the abundance of lung C/EBPβ mRNA after IgG immune 
complex deposition (Fig. 22C). Thus, the increased mRNA expression of C/EBPβ is 
consistent with the increased DNA binding activity in the lung. 
Alveolar macrophages play a key role in the IgG immune complex-induced lung 
injury (10, 61, 67). Therefore, I determined whether alveolar macrophage depletion would 
affect C/EBP activation in whole-lung tissues 4 h after onset of injury. Mice pretreated 
with PBS liposomes and challenged with IgG immune complexes showed the expected 
C/EBP activation (Fig. 23, lanes 1 and 2). By contrast, depletion of alveolar macrophages 
with Cl2MDP liposomes markedly reduced the extent of lung C/EBP activation (Fig. 23). 
These data suggest that alveolar macrophages play a critical role in IgG immune 












Figure 22. C/EBPβ and C/EBPδ DNA Binding Activities are Induced during IgG 
IC-induced Alveolitis. A, Mice lungs were challenged by IgG IC for indicated time periods. 
Then nuclear proteins were extracted from whole lung tissues and subjected to EMSA 
analysis. B, Nuclear proteins extracted from whole lung 0 and 4 h, respectively, after IgG 
immune complex deposition were subjected to supershift. The following antibodies (Abs) 
were used: normal rabbit IgG (N), anti-C/EBPα Ab (α), anti-C/EBPβ Ab (β), anti-C/EBPδ 
Ab (δ), anti-C/EBPε Ab (ε), and anti-C/EBP Ab (). Arrows indicated supershifts and 
C/EBP dimers, respectively. The same experiment was repeated 3 times. C, RNAs were 
extracted from lung homogenates 0, 1, 2, 4, 8, and 24 h after initiation of IgG immune 
complex reactions. Real-time PCR was then used to analyze mRNA expression of C/EBPβ 
during IgG immune complex-induced lung injury. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. Results are means ± S.E., n=4. The same experiment was repeated once.
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Figure 23. Effects of Alveolar Macrophage Depletion on C/EBP Activation during IgG 
Immune Complex-induced Lung Injury. Mice received PBS-liposome or Cl2MDP- 
liposomes 24 h before receiving intratracheal challenge with IgG immune complex. Four 
hours after immune complex challenge, lungs were harvested. C/EBP-binding activity of 
whole lung nuclear extracts was assessed by EMSA. The same experiment was repeated 
four times. 
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Effects of C/EBPβ Deficiency on IgG Immune Complex-induced Lung Injury 
I sought to determine whether C/EBPβ contributed to IgG IC-induced lung injury 
by using C/EBPβ deficient mice. As shown in Fig. 24A, C/EBPβ deficiency resulted in a 
significant decrease (p < 0.001) of permeability index (albumin leakage) when compared 
with wild-type mice after IgG IC deposition. I also examined MPO content to evaluate 
neutrophil accumulation in lungs (Fig. 24B). As with albumin leakage, MPO content in 
C/EBPβ deficient mice was much lower (p < 0.01) when compared with values in 
control-treated wild type mice during lung injury. I further found that C/EBPβ deficient 
mice displayed significant attenuation of the total number of white blood cells (WBCs) (by 
59%, p < 0.001; Fig. 24C) and neutrophils (by 61%, p < 0.001; Fig. 24D) in BAL fluids 
from IgG IC-injured lung compared with wild-type mice. I examined whether C/EBPβ 
deficient mice exhibited reduced lung injury by histological analyses. As shown in Fig. 25, 
both wild type and C/EBPβ deficient control mice exhibited normal lung architecture. As 
expected, lung hemorrhage and inflammatory cell influx were observed in wild-type mice 
after IgG immune complex deposition. In contrast, IgG immune complex-injured lungs 
from C/EBPβ deficient mice showed significantly decreased neutrophil accumulation and 
reduced intra-alveolar hemorrhage compared with wild type animals. 
Production of Cytokines and Chemokines in Lung after IgG Immune Complex Deposition 
is Impaired in C/EBPβ Deficient Mice 
 
I determined BAL levels of several inflammatory cytokines and chemokines that 
are involved in IgG immune complex-induced lung injury (10). As expected, wild type 
mice undergoing IgG immune complex deposition showed increased production of TNF-α, 














Figure 24. Effects of C/EBPβ Deficiency on IgG Immune Complex-induced Pulmonary 
Inflammation. Four hours after IgG immune complex deposition, BAL fluids and lungs 
were harvested. A, mouse albumin content in BAL fluids was determined using ELISA. 
The permeability index was expressed as the ratio of the albumin in the IgG immune 
complex-injured lungs versus that in the control-treated lungs of same type of mice. B, 
changes in lung MPO activity was measured as a marker for pulmonary neutrophil 
accumulation. Total cell accumulation (C), and neutrophil influx (D) in BAL fluids were 
counted. Results are means ± S.E. for three (control group) or five (IgG immune 








































Figure 25. Effects of C/EBPβ Deficiency on IgG IC-induced Lung Injury Bases on 
Histological Assay. Lung sections were stained with H&E (original magnification × 40). 
Lung sections shown included the following: C/EBPβ+/+ + Ctrl, C/EBPβ+/+ + IgG IC, 
















Figure 26. Effects of C/EBPβ Deficiency on Proinflammatory Mediators’ Expressions 
during IgG IC-induced Acute Lung Injury. Four hours after IgG immune complex 
deposition, BAL fluids and lungs were harvested. Cell-free BAL fluids were subjected to 
ELISA to measure TNF-α (A), IL-6 (B), MIP-2 (C), KC (D), MIP-1 (E), and MIP-1 (F) 
levels. RNAs were extracted, and real-time PCR was then used to analyze mRNA 
expression of TNF-α (G), IL-6 (H), MIP-2 (I), KC (J), MIP-1 (K), and MIP-1 (L). 
Results are means ± S.E. for three (control group) or five (IgG immune 
complex-challenged group) mice for each group. The same experiment was repeated once. 
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all these inflammatory mediators were dramatically decreased in IgG immune 
complex-injured mutant mice when compared with wild type mice. Moreover, in the 
presence of IgG immune complexes, lung from C/EBPβ deficient mice expressed 
considerably lower amounts of mRNAs for TNF-α, IL-6, MIP-2, KC, MIP-1α, and MIP-1β 
(Fig. 26G-L), compared with the lung from wild type mice. Adhesion molecules are also 
involved in lung inflammatory injury after intra-alveolar deposition of IgG immune 
complexes (219). Notably, IgG immune complex-injured lungs from C/EBPβ deficient 
mice showed a marked reduction in ICAM-1 mRNA, whereas very little decrease in 
VCAM-1 expression was observed (Fig. 27). Because soluble ICAM-1 can directly bind 
and activate lung macrophages, and enhance lung injury after intrapulmonary disposition 
of IgG immune complexes (196), I measured soluble ICAM-1 level in BAL fluids of IgG 
immune complex-injured lungs. I found that C/EBPβ deficiency resulted in a significant 
decrease (p < 0.01) of ICAM-1 change when compared with wild type mice after IgG 
immune complex deposition in the lung (Fig. 27). 
Effects of C/EBPβ Deficiency on Cytokine and Chemokine Protein Production in Alveolar 
Macrophages Stimulated by IgG IC 
 
I evaluated the effects of C/EBPβ deficiency on the expression of cytokines and 
chemokines in primary alveolar macrophages. Upon IgG immune complex treatment, 
C/EBPβ deficient alveolar macrophages released significantly less TNF-α, IL-6, MIP-2, 
KC, and MIP-1α than wild-type macrophages at all time points analyzed (Fig. 28). 
Interestingly, no significant change was found for MIP-1β, suggesting that other cells in 
the lung may contribute to the reduced levels of this chemokine in the BAL fluid and lung 















Figure 27. Effects of C/EBPβ Deficiency on IgG Immune Complex-induced ICAM-1 and 
VCAM-1 Expressions. Four hours after IgG immune complex deposition, BAL fluids and 
lungs were harvested. Real-time PCR was then used to analyze mRNA expression of 
ICAM-1 (A), and VCAM-1 (B). (C) Cell-free BAL fluids were subjected to ELISA to 
measure sICAM-1 level. The relative sICAM-1 level was expressed as the ratio of the 
sICAM-1 in the IgG immune complex-injured lungs versus that in the control-treated lungs 
of same type of mice. Results are means ± S.E. for three (control group) or five (IgG 


















Figure 28. Effects of C/EBPβ Deficiency on IgG immune Complex-induced Inflammatory 
Reactions in Alveolar Macrophages. Alveolar macrophages obtained from wild-type and 
C/EBPβ knockout mice were treated with 100 μg/ml IgG immune complexes for the times 
indicated, and supernatants were subjected to ELISA to assess production of TNF-α (A), 
IL-6 (B), MIP-2 (C), KC (D),  MIP-1α (E), and MIP-1β (F). The data were expressed as 
means ± S. E. (n = 6). The same experiment was repeated once. 
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for one time point, however, only 0.25 million primary alveolar macrophages could be 
harvested from each mouse. Thus, MH-S cells—alveolar macrophage-derived cell line, 
were used to determine the effects of IgG IC on C/EBP DNA binding activities in alveolar 
macrophage. As shown in Fig. 29A, C/EBP DNA binding activities was induced by IgG IC. 
To further determine which C/EBP family members were induced by IgG IC, supershift 
assays were performed. There are four major DNA-binding species in the nuclear proteins 
of control-treated macrophages, as follows: C/EBPβ LAP/C/EBP heterodimers; 
heterodimers between C/EBPβ LAP and LIP; LAP/LAP homodimers, and LIP/LIP 
homodimers. In IgG immune complex-treated macrophages, the DNA-binding activity of 
C/EBPβ (mainly LAP/LIP, and LAP/LAP) was induced (Fig. 29B). To examine the role of 
C/EBP in IgG IC-induced inflammation in MH-S cells, I ablated C/EBPβ expression by 
siRNA-mediated silencing (Fig. 30A). Analysis of inflammatory mediator production 
showed impaired induction by IgG immune complexes following C/EBPβ knockdown in 
MH-S cells (TNF-α decreased by 62%, IL-6 by 77%, and MIP-2 by 48%, respectively; Fig. 
30B-C).  
Effects of C/EBPβ Overexpression on IgG IC-induced TNF-α and IL-6 Expression in 
Alveolar Macrophages 
 
I examined IgG immune complex-induced C/EBP transcriptional activity in 
transiently transfected MH-S cells using 2 × C/EBP-Luc, a promoter-reporter that contains 
two copies of a C/EBP binding site, and an expression vector for C/EBPβ (liver enriched 
activating protein). Because the transfection efficiency is very low in primary alveolar 
macrophages, MH-S cells were used to conduct transfection. Consistent with the results 














Figure 29. C/EBPβ and C/EBPδ DNA Binding Activities are Upregulated in MH-S Cells 
during IgG IC-induced Inflammatory Responses. A, MH-S cells were challenged by 100 
μg/ml IgG IC for different time periods as indicated. Nuclear extracts were then extracted, 
and subjected to EMSA to detect C/EBP activity. B, Nuclear proteins extracted from MH-S 
cells, 0 and 4 h, respectively, after IgG immune complex challenge were subjected to 
supershift. The following antibodies (Abs) were used: normal rabbit IgG (N), anti-C/EBPα 
Ab (α), anti-C/EBPβ Ab (β), anti-C/EBPδ Ab (δ), anti-C/EBPε Ab (ε), and anti-C/EBP 
Ab (). Arrows indicated supershifts and C/EBP dimers, respectively. The same 















Figure 30. C/EBPβ is Required for IgG IC-induced TNF-α, IL-6 and MIP-2 Expressions in 
MH-S Cells. A, MH-S cells were transiently transfected with control siRNA or C/EBPβ 
siRNA. Twelve hours after transfection, RNAs were isolated. Then RT-PCR was 
performed by using primers for C/EBPβ, C/EBPδ, and GAPDH, respectively. The level of 
GAPDH was shown at the bottom as a loading control. Twelve hours after transfection, the 
cells were incubated with 100 μg/ml IgG immune complexes for 6 h. Supernatants were 
harvested, and ELISA was performed to investigate the expressions of TNF-α (B), IL-6 (C), 
and MIP-2 (D). The data were expressed as means ± S. E. (n = 12). The same experiment 
was repeated three times. 
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Figure 31. Effects of C/EBPβ on IgG Immune Complex-induced C/EBP DNA Binding in 
Alveolar Macrophage. MH-S cells were transiently transfected with total of 0.5 μg 
indicated DNA. Twenty four hours after transfection, the cells were challenged with 
indicated stimulus for 4 h. Cell lysates were used for luciferase activity assay. 
Luminometer values were normalized for expression from a cotransfected thymidine 
kinase reporter gene. The data were expressed as means of three experiments ± S. E. (n=3).  
The same experiment was reapted once. 
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luciferase activity compared with the untreated control (Fig. 31). C/EBPβ vector alone also 
elevated 2 × C/EBP-Luc transcription (7.7-fold). Importantly, IgG immune complex 
treatment of C/EBPβ transfectants induced luciferase expression 24-fold over the control 
value. Because these effects are super additive, IgG immune complexes may stimulate the  
intrinsic activity of C/EBPβ as well as its expression. 
I next evaluated the role of C/EBPβ in IgG immune complex-induced transcription 
from the TNF-α and IL-6 promoters. As shown in Fig. 32, IgG immune complex 
stimulation alone markedly increased luciferase activity (2.2-fold for TNF-α and 4.56-fold 
for IL-6). C/EBPβ overexpression in the absence of IgG immune complex resulted in 
4-fold (TNF-α) and 1.56-fold (IL-6) induction of luciferase expression. Importantly, IgG 
immune complex treatment of C/EBPβ transfectants induced luciferase expression 8.6-fold 
and 9.65-fold for TNF-α and IL-6, respectively. These data are consistent with the ELISA  
results obtained from primary macrophages and MH-S cells. 
Effects of C/EBPδ Deficiency on IgG Immune Complex-induced Lung Inflammation 
Because C/EBPδ DNA-binding activity was induced by IgG immune complex 
deposition in the lung, I examined whether C/EBPδ contributes to IgG immune 
complex-induced lung inflammatory responses. As shown in Fig. 33, there was no 
significant difference in lung MPO activity between wild-type and C/EBPδ deficient mice 
4 h after IgG immune complex deposition. Consistently, BAL fluids from lungs of C/EBPδ 
deficient mice showed similar levels of TNF-α and MIP-2 when compared with BAL 
fluids from injured wild-type mice (Fig. 34). I next determined the effects of C/EBPδ on 
the inflammatory mediator production from IgG immune complex-stimulated primary 
alveolar macrophages. As shown in Fig. 35, C/EBPδ deficiency in alveolar macrophages 
caused only modest decreases in TNF-α, MIP-2, KC, and MIP-1α production compared 
with wild type macrophages at all time points analyzed. Thus, C/EBPβ (but not C/EBPδ) is 














Figure 32. Effects of C/EBPβ Expression on IgG Immune Complex-induced TNF-α and 
IL-6 Production in MH-S Cells. MH-S cells were transiently transfected with total of 0.5 
μg indicated DNA. Twenty four hours after transfection, the cells were challenged with 
indicated stimulus for 4 h. Cell lysates were used for luciferase activity assay. 
Luminometer values were normalized for expression from a cotransfected thymidine 
kinase reporter gene. The data were expressed as means of three experiments ± S. E. (n=3). 
The same experiment was repeated three times. 
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Figure 33. Effects of C/EBPδ Deficiency on Neutrophil Influx during IgG IC-induced 
Acute Lung Injury. Four hours after IgG IC deposition, mice lungs were harvested, and 
changes in lung MPO activity was measured as a marker for pulmonary neutrophil 
accumulation. Results are means ± S.E. for six mice for each group. The same experiment 



















Figure 34. Effects of C/EBPδ Deficiency on TNF-α and MIP-2 Expressions during IgG 
Immune Complex-induced Acute Lung Injury. Four hours after IgG immune complex 
deposition, BAL fluids were harvested, and subjected to ELISA to measure TNF-α 



















Figure 35. Effects of C/EBPδ Deficiency on IgG IC-induced Inflammation in Alveolar 
Macrophages. Alveolar macrophages obtained from wild-type and C/EBPβ knockout mice 
were treated with 100 μg/ml IgG immune complexes for the times indicated, and 
supernatants were subjected to ELISA to assess production of TNF-α (A), MIP-2 (B), KC 
(C), and MIP-1α (D). The data were expressed as means ± S. E. (n = 6). The same  





Roles of C/EBPβ and –δ in IgG IC-induced Inflammation in Macrophages 
Macrophage FcR activation plays a central role in the immune defense system (6, 
193). However, the signaling pathways from FcRs to the nucleus remain largely unknown. 
In my study, I provide the evidence that C/EBPβ and -δ are key transcription factors that 
regulate FcR-mediated generation of inflammatory cytokines and chemokines in 
macrophages. To our knowledge, this is the first study indicating that C/EBPs are key 
regulators of immune complex-induced inflammatory responses. 
Increasing evidence suggests an important role for C/EBPs, such as C/EBPβ and -δ, 
in inflammation (199, 220, 221). For example, C/EBPβ has been shown to be an effector in 
the induction of acute phase and inflammatory genes responsive to LPS, IL-1, or IL-6 (109, 
222). C/EBPδ is relatively less well characterized than C/EBPβ. However, similarly to 
C/EBPβ, C/EBPδ has also been implicated in regulation of the acute phase and 
inflammatory responses (128, 148). Interestingly, a recent study demonstrates a critical 
role for C/EBPδ in a regulatory circuit that discriminates between transient and persistent 
TLR4 stimulation (220). In another study, Maitra et al. show that C/EBPδ is the key 
mediator to initiate low dose endotoxin-induced inflammation (207). Functional C/EBP 
binding sites have been identified in the promoter regions of the TNF-α, MIP-2, and 
MIP-1α (194, 223-225). For example, C/EBPβ has been shown to play an important role in 
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the regulation of the TNF-α gene in myelomonocytic cells (223). Furthermore, serial and 
site-directed deletion mutants of MIP-2 luciferase reporter genes demonstrate that the 
binding sites for both C/EBPβ and NF-κB are essential for the activation of the MIP-2 
promoter in response to nitric oxide (224). In addition, a recent study suggests that both 
C/EBPβ and NF-κB are involved in the upregulation of MIP-1α expression in 
chondrocytes treated with IL-1β (225). Using monocytic cells, Fernández et al. recently 
show that cross-linking of FcR induces C/EBPβ DNA binding to its binding site in the 
MIP-1α promoter, which suggests the possible involvement of C/EBPβ in IC-induced 
MIP-1α expression (194). However, whether and to what extent C/EBPβ and -δ contribute 
to FcR-mediated inflammatory mediator production has been unclear. My study shows 
that C/EBPβ and -δ are expressed in untreated macrophages, and IgG IC stimulation 
upregulates C/EBPβ and -δ activities. Using a siRNA-mediated knockdown approach and 
mice deficient for C/EBPβ or/and -δ, my results clearly demonstrate that C/EBPβ and -δ 
play critical roles in the production of TNF-α, MIP-2, and MIP-1α in IgG IC-stimulated 
macrophages. Interestingly, the functions of C/EBPβ and -δ seem to be partially redundant, 
although lack of either protein has a significant effect on TNF-α, MIP-2, and MIP-1α 
production. This could also indicate the importance of C/EBPβ and-δ heterodimer 
occupancy in regulating these promoters. This hypothesis is further supported by data 
showing that co-expression of C/EBPβ- and C/EBPδ-expressing vectors stimulates more 
expression of a C/EBP-driven luciferase reporter than either C/EBPβ or C/EBPδ alone (Fig. 
2). Further, because a relatively low level of DNA binding for C/EBPδ contributes a 
vigorous induction of TNF-α, MIP-2, and MIP-1α, it is tempting to speculate that C/EBPδ 
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may be more effective than C/EBPβ in supporting the IgG IC-induced transcription of 
TNF-α, MIP-2, and MIP-1α genes. 
Although the primary mechanism of C/EBPβ regulation within inflammatory 
responses appears to be post-transcriptional, C/EBPβ mRNA levels are also induced by 
inflammatory stimuli, including LPS (109, 226). On the other hand, unlike C/EBPβ, the 
primary mechanism of C/EBPδ regulation within the inflammatory responses is 
transcriptional (148, 226). For example, LPS, IL-1, and IL-6 all can induce C/EBPδ 
expression at the mRNA level (222). Here I show that IgG IC induces C/EBPβ and -δ 
expressions at both mRNA and protein levels. Further, the DNA binding activities of both 
C/EBPβ and -δ are increased upon FcR activation, although whether this is due solely to 
increased expressions of the proteins versus post-translational regulation of C/EBP protein 
activity is unknown and requires further investigation. 
Using MAPK inhibitors, previous studies have shown that activation of MAPK is 
necessary for the FcR-dependent induction of TNF-α expression in monocytes (227). 
Furthermore, FcR ligation of monocytes/macrophages leads to both ERK1/2 and p38 
activation (228, 229). In addition, Song et al. demonstrate that in microglia, the 
Ras/MEK/ERK pathway is necessary and sufficient for IC-induced MIP-1α expression 
(230). Thus, my finding that IgG IC treatment leads to the phosphorylation of ERK1/2 and 
p38 MAPK is consistent with these previous reports. Importantly, my results suggest that 
both ERK and p38 MAPK pathways are involved in IgG IC-induced C/EBPβ and -δ 
activation, thus stimulating cytokine and chemokine production in macrophages. 
Interestingly, neither ERK nor p38 MAPK affects NF-κB DNA binding activity, 
suggesting that other signaling pathways are involved in its activation by IgG IC. This is 
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consistent with a previous report showing that a mitogen-activated protein kinase kinase 
(MEK) inhibitor fails to affect IC-induced p65 nuclear translocation in microglia (230). In 
contrast, other studies have suggested that MAPK activation is necessary for 
FcR-dependent activation of NF-κB in monocytes (231-233). Collectively, however, 
these data do not exclude the requirement for NF-κB activation in FcR-mediated 
inflammation. In the current study, IgG IC-stimulated production of TNF-α, MIP-2, and 
MIP-1α is inhibited by a NF-κB inhibitor with a significant effect observed on TNF-α and 
MIP-1α levels (Fig. 11). These data suggest that NF-κB may play important but differential 
regulatory roles in FcR-mediated inflammatory mediators’ production. 
Products of macrophages play a major role in events leading to tissue injury. TNF-α, 
other cytokines, and chemokines, such as MIP-2 and MIP-1α, secreted by macrophages 
have been shown to modulate the cell signaling cascades for the production of other 
proinflammatory and anti-inflammatory mediators during inflammation. The coordinate 
expressions of activating and inhibitory FcRs on macrophages and other cells thus ensure 
the homeostasis of IC-induced inflammatory responses. For example, genetic deletion of 
FcR -chain, which leads to the loss of cell surface expression and functional inactivation 
of all three activating FcRs, results in dramatically impaired inflammatory responses 
associated with IC formation (193, 214). In contrast, enhanced macrophage responses are 
observed in FcRⅡ knockout mice (193, 214). Using macrophages from mice lacking FcR 
-chain (FcR), we demonstrate that activation of C/EBPβ and -δ in macrophages by IgG 
IC stimulation is mediated, to a large extent, by activating FcRs. Furthermore, we show an 
enhanced C/EBP DNA binding activity in macrophages from FcRⅡ deficient mice. 
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These data further suggest that activation of C/EBPβ and –δ may function as a pivotal 
regulatory mechanism of IgG IC-associated immune responses. 
Another interesting result in my study is that C5a enhances IgG IC-induced 
cytokine and chemokine production by elevating C/EBPs but not NF-κB DNA binding 
activities. However, the exact mechanism whereby C5a signals control C/EBP activation 
remains an important open question. Several inflammatory stimulators, such as TNF, 
IFN-, and LPS have been shown to upregulate activating FcR production (193, 214, 234). 
Recent studies have shown that C5a causes induction of FcRⅢ and suppression of FcR
Ⅱ on both alveolar macrophages and RAW264.7 cells (216, 235, 236). Furthermore, 
genetic ablation of C5aR expression completely abolishes this regulation of FcRs. These 
studies provide definite evidence that C5a plays a critical role in regulating the FcRⅢ/Ⅱ 
pair to connect complement and FcR pathways during IC-associated inflammation. 
Moreover, the current data suggest that the enhancement by C5a of C/EBP activity may be 
mediated by increased phospho-p38 MAPK and phosphop-44/42 MAPK levels. 
Interestingly, my finding that the interaction between C5a and C5aR has no effect on IgG 
IC-induced NF-κB activation suggests that the C5a/C5aR pathway may have a specific 
role in C/EBP activation. 
In summary, for this part of my study, Fc receptors-mediated activation of 
C/EBPβ and -δ leads to cytokine and chemokine production from IgG IC-stimulated 
macrophages, and both MAPKs and C5a signal pathways are involved in C/EBP activation 
(Fig. 36). These data support an important role of C/EBPβ and -δ in immune 















Figure 36. Cell Signaling Transduction Pathways from Membrane Receptors (FcRs and 
C5aR) to Nucleus in Peritoneal Macrophages Challenged by IgG IC. Cross-linking of 
activating FcRs leads to activation of p38 and p44/42 MAPKs, which can be further 
enhanced by interaction between C5a and C5aR. Phosphorylation of MAPKs results in 
elevated C/EBP and - DNA binding activities, which can finally promote 
inflammation-related gene transcription. FcRⅡas an inhibitory receptor could suppress 




factors in regulating the network of inflammatory system may be a crucial step for the 
development of new therapeutic drugs for treatment of immune complex diseases. 
Roles of C/EBPβ and –δ in IgG IC-induced ALI 
The intrapulmonary deposition of IgG immune complexes in mice results in a 
complex cascade of inflammatory responses that control an ordered sequence of events, 
including the activation of residential macrophages and recruitment of neutrophils to the 
site of injury (10). Previous studies in this lung model suggest that activation of NF-κB 
appears to play a central role in the pulmonary inflammatory response to IgG immune 
complexes (68). However, no direct evidence supports this hypothesis. Moreover, growing 
evidence indicates that the regulation of gene expression in the lung is mediated by a highly 
intricate network of transcription factors (77, 237). Our recent studies show that STAT3 is 
activated in both alveolar macrophages and whole lung extracts following IgG immune 
complex deposition (62, 93). Using an adenoviral vector expressing a dominant-negative 
STAT3 isoform, we further show that STAT3 plays an important regulatory role in the 
pathogenesis of IgG immune complex-induced acute lung injury (93). Because the 
promoter regions of several important inflammatory mediators such as IL-6 and TNF-α do 
not contain functional STAT3 binding sites, the molecular mechanism whereby STAT3 
regulates lung inflammation remains unknown. Interestingly, it has been demonstrated that 
STAT3 can bind the promoter regions of both C/EBPβ and C/EBPδ, which are involved in 
IL-6 signaling in hepatoma cells (192). Thus, we hypothesize that STAT3 may regulate 
lung inflammation by affecting C/EBP activity. In the current study, I have identified 
C/EBPβ as a critical mediator of IgG immune complex-induced acute lung injury and 
inflammatory response in alveolar macrophages. 
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C/EBPβ and C/EBPδ are expressed in many tissues, including lung. However, the 
expression and function of C/EBPβ and C/EBPδ during acute lung inflammatory response 
are still largely unknown. My current study provides evidence that both C/EBPβ and 
C/EBPδ are activated in lung during IgG immune complex-induced acute lung injury. I 
further show the IgG immune complexes regulate the lung expression of C/EBPβ at mRNA 
level (Fig. 22C). However, the molecular mechanisms by which IgG immune complexes 
induce C/EBPβ gene expression in the lung remain unclear. I have found that C/EBP 
activation in peritoneal macrophages is mediated, to a large extent, by Fc receptors (FcR
Ⅰand FcRⅢ). Therefore, it would be interesting to investigate in the future study 
whether FcR signaling cascade is involved in the C/EBP activation after IgG immune 
complex deposition in the lung. 
C/EBPβ is a known regulator of several genes that are involved in the inflammatory 
responses, including those coding for cytokines, chemokines, and their receptors and 
acute-phase proteins (182). In the current study, I have used C/EBPβ deficient mice to 
clearly demonstrate that C/EBPβ plays a critical role in acute lung inflammation and injury. 
The current data indicate that several mechanisms are involved in C/EBPβ regulation of 
acute immunological pulmonary alveolitis. The results that C/EBPβ deficiency 
significantly mitigates IgG immune complex-induced lung injury as defined by decreased 
albumin leakage into lung and reduced MPO content as well as less BAL cells indicate a 
critical role for C/EBPβ in neutrophil accumulation in lungs. Neutrophil transmigration 
into the alveolar compartment and lung interstitium plays a key role in the development of 
acute lung injury. Using an antibody-mediated blocking approach, both the CXC 
chemokines (MIP-2 and KC) and CC chemokines (MIP-1α and MIP-1β) have been shown 
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to play an important role in intrapulmonary recruitment of neutrophils and development of 
lung injury induced by the IgG immune complex deposition (238-240). My observation 
that C/EBPβ deficiency resulted in a significant decrease of these chemokines in BAL 
fluids from IgG immune complex-injured lungs supports this hypothesis. Another possible 
mechanism is the C/EBPβ regulation of TNF-α and IL-6, both of which play an important 
role in the development of acute lung injury by inducing the expression of molecules 
mediating adhesive interactions between endothelial cells and leukocytes (241). Indeed, I 
show that C/EBPβ deficiency causes a reduced expression of TNF-α and IL-6 as well as 
ICAM-1 in the lung. Together, the data suggest that upon IgG immune complex deposition, 
C/EBPβ affects neutrophil migration into lung and alveolar space by regulating the 
expression of chemokines, cytokines, and adhesion molecule. 
Alveolar macrophages function as regulatory cells that secrete TNF-α and other 
cytokines and chemokines to modulate the cell signaling cascade for the production of 
other inflammatory mediators during lung inflammation (182). I previously showed that 
depletion of alveolar macrophages results in significantly reduced expression of 
inflammatory cytokines and chemokine genes in IgG immune complex-injured rat lungs 
(62). Data in the current study show that C/EBP activation induced by IgG immune 
complexes is suppressed by depletion of alveolar macrophages in whole lung tissues (Fig. 
23). Moreover, employing mice deficient for C/EBPβ, siRNA-mediated knockdown in cell 
lines, and luciferase reporter assays, I show that C/EBPβ plays a critical role in the 
production of cytokines and chemokines in IgG immune complex-stimulated macrophages. 
These data together indicate that C/EBPβ activation in alveolar macrophages is a key event 
in IgG immune complex-induced lung injury. 
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All C/EBP members can form homo- and heterodimers with other family members. 
It has been noted that, depending on the composition, C/EBP complexes may be associated 
with functional differences in cell growth, cell activation, and apoptosis (242). However, 
several studies have suggested compensatory or redundant roles for C/EBPs, including 
C/EBPβ and C/EBPδ, in supporting the induction of inflammatory cytokines and 
chemokines. For example, LPS stimulation of peritoneal macrophages from C/EBPβ 
deficient mice leads to normal induction of several inflammatory cytokines, including IL-6 
and TNF-α, with the exception of G-CSF, Mincle, and mPGES-1 (143, 184, 197, 198). 
Using a B lymphoblast system, Hu et al. reports that the activities of C/EBPα, C/EBPβ, and 
C/EBPδ are redundant in regard to the expression of IL-6 and MCP-1 (126). In addition, a 
recent study shows that C/EBPδ deficient macrophages have no significant defects in IL-6 
and TNF-α production in response to several TLR ligands, whereas the absence of both 
C/EBPβ and C/EBPδ results in a significant decrease in the TLR ligand-induced 
production of IL-6 and TNF-α (206). Interestingly, our in vitro study shows that lack of 
either C/EBPβ or C/EBPδ has a significant effect on the production of TNF-α, MIP-2, and 
MIP-1α in IgG immune complex-stimulated peritoneal macrophages, indicating the 
possible importance of C/EBPβ and C/EBPδ heterodimer occupancy in regulating 
activation of these promoters. In addition, I have directly compared the effect of C/EBPβ 
and C/EBPδ deficiency on lung inflammatory responses. I clearly show that C/EBPδ could 
not compensate for C/EBPβ deficiency in the IgG immune complex lung injury model and 
alveolar macrophage responses. These data further support the idea that the functional 
roles of C/EBPβ and C/EBPδ in inflammation are cell and tissue specific.  
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Together, I present evidence that mutant mice defective in C/EBPβ but not C/EBPδ 
are significantly protected from acute lung inflammation and injury following 
intrapulmonary deposition of IgG immune complexes. My study indicates that 
understanding the underlying roles of various transcriptional factors in regulating the 
pulmonary inflammation may be a crucial step for devising new therapeutic strategies for 


































































C/EBP, CCAAT/enhancer-binding protein 
FcγR, Fcγ receptor 
IgG IC, immunoglobulin G immune complex 
siRNA, small interfering RNA 
TNF-α, tumor necrosis factor-α 
MIP-2, macrophage inflammatory protein-2 
MIP-1α, macrophage inflammatory protein-1α 
ERK, extracellular signal-regulated kinase  
MAPK, mitogen activated protein kinase 
C5a, complement component 5a 
ALI, acute lung injury 
ARDS, acute respiratory distress syndrome 
BSA, bovine serum albumin 
ITAM, immunoreceptor tyrosine-based activation motif 
ITIM, immunoreceptor tyrosine-based inhibition motif 
miR, microRNA 
IL, interleukin 
CLP, caecal ligation and puncture 
TF, tissue factor 
FASP, factorⅦ-activating protease 
LPS, lipopolysaccharide 
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IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells 
CD, cluster of differentiation molecule 
HUVECs, human umbilical vein endothelial cells 
HBECs, human bronchial epithelial cells 
PMNs, polymorphonuclear neutrophils 
CVF, cobra venom factor 
VCAM-1, vascular cell adhesion protein 1 
ICAM-1, intercellular adhesion molecule 1 
MDMEC, mouse dermal microvascular endothelial cell 
IFN-, interferon-gamma 
MCP-1, monocyte chemotactic protein-1 
BAL, bronchoalveolar lavage 
MPO, myeloperoxidase  
CINC, cytokine-induced neutrophil chemoattractant 
MIP-1β, macrophage inflammatory protein 1 beta 
C5aR, C5a receptor 
C5L2, C5a receptor-like 2 
C5AR1, complement component 5a receptor 1 
AECs, alveolar epithelial cells 




AHR, airway hyperresponsiveness 
KC, keratinocyte-activated cytokine 
AP-1, Activator Protein-1  
STAT3, Signal Transducer and Activator of Transcription 3 
RHD, Rel homology domain 
IKKβ, inhibitor of nuclear factor kappa-B kinase subunit beta 
ROS, reactive oxygen species 
NADPH, Nicotinamide Adenine Dinucleotide Phosphate, reduced 
NAC, N-acetylcysteine  
ATF, activating transcription factor 
JAK, Janus kinase 
SOCS3, suppressor of cytokine signaling 3 
bZIP, basic region-leucine zipper 
COPD, chronic obstructive pulmonary disease 
LAP*, liver-enriched transcriptional activator protein*  
LAP, liver-enriched transcriptional activator protein 
LIP, liver-enriched inhibitory protein 
TLRs, Toll-like receptors 
CCSP, Clara cell secretory protein 
RSK, ribosomal S-6 kinase 
cAMP, cyclic adenosine 3', 5'-monophosphate 
DIC, disseminated intravascular coagulation 
IL-1Ra, interleukin-1 receptor antagonist 
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HIV, human immunodeficiency virus 
NK cell, natural killer cell 
CHOP, C/EBP homologous protein 
ER, endoplasmic reticulum 
IPF, idiopathic pulmonary fibrosis 
Bax, Bcl-2–associated X 
G-CSF, granulocyte colony-stimulating factor 
mPGES-1, microsomal prostaglandin E synthase-1 
EMSA, Electrophoretic Mobility Shift Assay 
i.p., intraperitoneal 
i.v., intravenous 
Cl2MDP, dichloromethylene diphosphonate 
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